Category: For physicians

  • Title card for Your Gut Is Reaching Your Spine, The Angry Gut Chapter 11, with Dr. Padda presenting

    HLA-B27 and Ulcerative Colitis: Screening for Spinal Involvement

    Your Gut Is Reaching Your Spine | The Angry Gut, Chapter 11

    HLA-B27 and Ulcerative Colitis: Screening for Spinal Involvement

    HLA-B27 sharply raises the risk of spinal disease in ulcerative colitis: in pooled cohorts, carriers had a relative risk of 22.17 for ankylosing spondylitis. Across 71 studies of inflammatory bowel disease, 10% of patients had sacroiliitis and 3% ankylosing spondylitis, yet axial symptoms are rarely asked about.

    Axial involvement in inflammatory bowel disease is common, gene-sorted and rarely asked about. Neither the gastroenterology visit nor the spine workup is built to catch it.

    HLA-B27 is the sharpest available risk marker for axial disease in ulcerative colitis, and the HLA-B27 ulcerative colitis patient is seldom screened for it. In a meta-analysis of ulcerative colitis cohorts, carriage conferred a relative risk of 22.17 for ankylosing spondylitis, and 68.29% of those who developed it were carriers against 31.71% who were not. Because just three of the pooled studies recorded carrier status, the confidence around that figure is broad.

    In the video Your Gut Is Reaching Your Spine, Chapter 11 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, the gut-to-spine evidence is sorted into tiers: inflammatory spread that is established, and a disc microbiome hypothesis that is not. For the physician, the established tier is the actionable one. It defines whom to ask, what to order, where to refer and what to document.

    How common is spine involvement in ulcerative colitis and IBD?

    Across 71 studies, prevalence in inflammatory bowel disease was 10% for sacroiliitis, 3% for ankylosing spondylitis and 13% for peripheral arthritis. Only three incidence studies exist, with follow-up windows of 5 to 30 years, so prevalence is well described and rate of onset is not. A 52-study synthesis of 352,454 patients reported at least one extraintestinal manifestation in 24%, with subtype figures of 27% for ulcerative colitis and 35% for Crohn’s disease drawn from different pooled subsets, and axial involvement at comparable rates in both.

    The arrow also runs in reverse. Of 108 patients with ankylosing spondylitis and no known bowel disease who underwent ileocolonoscopy, 40 had inflammatory lesions and 17 had a diagnosable disease: Crohn’s in 12, intestinal tuberculosis in 4 and ulcerative colitis in 1. Among those scoped purely as screening, 17.6% showed abnormalities, predominantly erosions and ulcers. That series was retrospective, single-center, symptom-enriched and unadjusted for NSAID exposure.

    The miss is structural rather than a knowledge gap. Gastroenterology follow-up is organized around the bowel, the spine pathway around the disc, and neither visit template carries the question that links them.

    How does HLA-B27 link gut and spine inflammation?

    HLA-B27 transgenic rats develop gut and joint inflammation; raised without microbial colonization they develop neither, while skin and genital lesions still appear. In human ileal biopsies, interleukin-23 is overexpressed in ankylosing spondylitis without a matching rise in interleukin-17. Spondylitis gut biopsies also show inflammasome expression roughly tenfold above controls (NLRP3 fold induction 22.2 versus 2.33), with NLRP3 correlating with spinal disease activity at r = 0.28, a modest association.

    The management implication is concrete. An interleukin-17A antagonist that performs in axial disease was ineffective in Crohn’s disease, with outcomes worse than placebo, in a phase II trial in which 18 of 59 patients discontinued early. In a patient carrying both diagnoses, a therapy chosen for the spine can work against the bowel, which means the axial diagnosis should be made and shared before that choice.

    Imaging findings and the antibiotic request

    The lumbar MRI rarely settles the question. Modic changes are present in about 6% of asymptomatic people and a median 43% of those with back pain; type 1 carries an odds ratio of 4.01 for pain, while unspecified Modic change carries 1.62 with an interval spanning one. Patients who have read about disc bacteria may request antibiotics. The Norwegian multicenter trial prespecified a minimal important difference of 4 points and found −1.6, with −2.3 in type 1 and −0.1 in type 2, and drug-related adverse events of 56% against 34%. The 2026 Australian trial found a twelve-month pain difference of 0.06 on a 0-to-10 scale, though only six of 170 participants had type 1 changes alone.

    What Measura measures, and what it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] does not image the sacroiliac joints, scope the bowel, sequence stool or perform HLA typing; those remain with the ordering physician and specialists. What the protocol contributes is a documented terrain in the same patient:

    None of these diagnoses spondyloarthritis. They document the upstream drivers of a breached barrier: acellular carbohydrates that deplete short-chain fatty acid producers, industrial seed oils, sleep lost to night pain, and metaflammation beneath all of them. In a pilot of surgical patients with disc disease, 20 per subgroup, stool showed depleted short-chain fatty acid producers while CRP ran elevated. How results are structured for the chart is covered in interpreting the report.

    A workflow for the inflammatory bowel disease panel

    1. Add an inflammatory back pain screen to bowel disease visits: nocturnal pain in the second half of the night, morning stiffness beyond half an hour, improvement with activity and worsening with rest.
    2. For positive screens, order HLA-B27 and route to rheumatology for sacroiliac assessment rather than repeating lumbar imaging.
    3. Communicate an axial diagnosis to gastroenterology before biologic selection.
    4. Document the metabolic and autonomic terrain at baseline and at reassessment.
    5. Build the screen into standing orders so it does not depend on which specialist the patient saw that day.

    The same malabsorbing bowel drives the deficiency discussed in vitamin D screening and falls risk. Specialty-specific uses are outlined in specialty applications, and the complete evidence file is the Chapter 11 Deep Dive.

    Frequently asked questions

    What proportion of IBD patients have axial spondyloarthritis?

    Pooled prevalence across 71 studies was 10% for sacroiliitis and 3% for ankylosing spondylitis, with 13% peripheral arthritis. Incidence is poorly characterized, with only three studies reporting it over follow-up of 5 to 30 years. Axial involvement ran at similar rates in Crohn’s disease and ulcerative colitis in a larger synthesis. Criteria for which patients to evaluate are summarized in selection criteria.

    Should HLA-B27 be ordered in every patient with ulcerative colitis?

    A history-triggered approach is the practical option. Carriage conferred a relative risk of 22.17 for ankylosing spondylitis in ulcerative colitis, but only three pooled studies reported carrier status. An inflammatory back pain history gives a clear trigger for ordering and referral. HLA typing is not a Measura test and is ordered through the treating physician. The protocol logic is addressed in clinical rationale.

    Does interleukin-17 blockade affect the bowel in patients with both conditions?

    In Crohn’s disease, an interleukin-17A antagonist was ineffective, with outcomes worse than placebo, in a phase II trial of 59 patients, 18 of whom discontinued early. Interleukin-23 is overexpressed in the spondylitis gut without interleukin-17. Coordinating the choice with gastroenterology is the prudent course. Structured sharing of results across services is described in getting results into the record.

    Are antibiotics indicated for Modic changes in patients with IBD?

    Current trials do not support routine use. The Norwegian trial found −1.6 points against a minimal important difference of 4, and the 2026 Australian trial found a twelve-month pain difference of 0.06, with adverse events in 40.0% against 23.5%. A disc without blood supply is a poor target for oral therapy. Longitudinal follow-up between visits is covered in chronic care and between-visit monitoring.

    Can Measura testing detect enteropathic spondyloarthritis?

    No. Measura does not perform imaging, endoscopy, stool analysis or HLA typing. It documents the metabolic, body-composition and autonomic terrain in the same patient, which complements the rheumatology and gastroenterology workup rather than replacing any part of it. Common questions about scope and ordering are answered in physician questions.

    What does a positive HLA-B27 mean if you have ulcerative colitis?

    It marks a much higher chance of spinal arthritis. In pooled ulcerative colitis cohorts, carriers had a relative risk of 22.17 for ankylosing spondylitis, and 68.29% of those who developed it were carriers. Only three of the pooled studies recorded carrier status, so the exact size of the risk is uncertain. A positive result with inflammatory back pain belongs with rheumatology for a sacroiliac assessment.

    What are the signs of inflammatory back pain?

    Four features point to it: pain in the second half of the night, morning stiffness lasting longer than half an hour, pain that improves with activity, and pain that worsens with rest. In a patient with inflammatory bowel disease, a positive screen calls for HLA-B27 testing and a rheumatology referral for sacroiliac assessment rather than another lumbar scan. The screen belongs in every bowel disease visit.

    Can ankylosing spondylitis point to hidden bowel disease?

    Yes, the link runs both ways. Of 108 patients with ankylosing spondylitis and no known bowel disease who had an ileocolonoscopy, 40 had inflammatory lesions and 17 had a diagnosable disease, most often Crohn’s. The series was retrospective, single-center and weighted toward patients with symptoms, so treat it as a reason to ask spondylitis patients about their bowels, not as a rate.

    Screen the IBD Panel for Axial Disease

    Learn how the Measura protocol adds documented metabolic, body-composition and autonomic measures to an inflammatory bowel disease panel, alongside standing orders for inflammatory back pain screening.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Lin, A., Tan, Y., Chen, J., Liu, X., & Wu, J. (2023). Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis. PLoS One, 18(8), e0289021. https://doi.org/10.1371/journal.pone.0289021
    • Karreman, M. C., Luime, J. J., Hazes, J. M. W., & Weel, A. E. A. M. (2017). The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn’s & Colitis, 11(5), 631–642. https://doi.org/10.1093/ecco-jcc/jjw199
    • Kilic, Y., Kamal, S., Jaffar, F., Sriranganathan, D., Quraishi, M. N., & Segal, J. P. (2024). Prevalence of extraintestinal manifestations in inflammatory bowel disease: A systematic review and meta-analysis. Inflammatory Bowel Diseases, 30(2), 230-239. https://doi.org/10.1093/ibd/izad061
    • Ahn, S. M., Kim, Y.-G., Bae, S.-H., Lim, D.-H., Hong, S., Park, S. H., Lee, C.-K., & Yoo, B. (2017). Ileocolonoscopic findings in patients with ankylosing spondylitis: A single center retrospective study. The Korean Journal of Internal Medicine, 32(5), 916-922. https://doi.org/10.3904/kjim.2015.313
    • Taurog, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernández-Sueiro, J. L., Balish, E., & Hammer, R. E. (1994). The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine, 180(6), 2359–2364. https://doi.org/10.1084/jem.180.6.2359
    • Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., & Travis, S. P. L. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 61(12), 1693–1700. https://doi.org/10.1136/gutjnl-2011-301668
    • Guggino, G., Mauro, D., Rizzo, A., Alessandro, R., Raimondo, S., Bergot, A.-S., Rahman, M. A., Ellis, J. J., Milling, S., Lories, R., Elewaut, D., Brown, M. A., Thomas, R., & Ciccia, F. (2021). Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis. Arthritis & Rheumatology, 73(7), 1189-1199. https://doi.org/10.1002/art.41644
    • Bråten, L. C. H., Rolfsen, M. P., Espeland, A., Wigemyr, M., Aßmus, J., Froholdt, A., Haugen, A. J., Marchand, G. H., Kristoffersen, P. M., Lutro, O., Randen, S., Wilhelmsen, M., Winsvold, B. S., Kadar, T. I., Holmgard, T. E., Vigeland, M. D., Vetti, N., Nygaard, Ø. P., Lie, B. A., … Zwart, J.-A. (2019). Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ, 367, l5654. https://doi.org/10.1136/bmj.l5654
    • Brinjikji, W., Diehn, F. E., Jarvik, J. G., Carr, C. M., Kallmes, D. F., Murad, M. H., & Luetmer, P. H. (2015). MRI findings of disc degeneration are more prevalent in adults with low back pain than in asymptomatic controls: A systematic review and meta-analysis. AJNR. American Journal of Neuroradiology, 36(12), 2394–2399. https://doi.org/10.3174/ajnr.A4498
    • Cicuttini, F. M., Wluka, A. E., Pan, F., O’Sullivan, R., Leder, K., Cheng, A. C., & Urquhart, D. M. (2026). Efficacy of antibiotics for chronic low back pain with disc herniation: a randomized clinical trial. JAMA Network Open, 9(5), e2612848. https://doi.org/10.1001/jamanetworkopen.2026.12848

    Related reading

  • Title card for Vitamin D Is a Hormone, Not a Vitamin, The Angry Gut Chapter 10, with Dr. Padda presenting

    Vitamin D Screening: Who Has an Indication and What Falls Risk Adds

    Vitamin D Is a Hormone, Not a Vitamin | The Angry Gut, Chapter 10

    Vitamin D Screening: Who Has an Indication and What Falls Risk Adds

    Vitamin D screening has an indication in malabsorption (inflammatory bowel disease, prior bowel surgery, celiac disease, post-bariatric anatomy), in darker skin at high latitude and in adiposity. Fall risk adds a documented balance baseline before any dosing schedule is chosen, because the harm signal in the dosing trials is falls.

    Routine vitamin D testing is out of favor for the general population. Patients with malabsorption, dyslipidemia and fall risk were never the population that recommendation addressed.

    Vitamin D screening in primary care has a clear guideline answer for the general population and almost none for the patients who generate the most questions. The 2024 Endocrine Society panel recommends against routine testing of 25-hydroxyvitamin D across the populations it reviewed, and against dosing above the dietary reference intake for disease prevention. Its scope statement is the operative line: it addresses people without an established indication.

    In the video Vitamin D Is a Hormone, Not a Vitamin, Chapter 10 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, the argument is endocrine: a governed axis adapts to excess and punishes bolus dosing. For the physician the operational questions are narrower. Who has an indication, what distorts the value before interpretation, and why fall-risk assessment belongs in the same order set.

    Is vitamin D screening necessary?

    The systematic review behind the guideline screened 37,007 citations and retained 151 studies. It identified no trials of screening itself. The recommendation against testing therefore reflects a test-and-treat strategy that has never been trialed, not a negative trial of one. The same panel names four groups for empiric supplementation without testing (ages 1 to 18, adults over 75, pregnancy and high-risk prediabetes), prefers daily over intermittent high doses in adults over 50 with an indication, and concedes that optimal doses remain unclear.

    That leaves the indicated patient to clinical judgment, which is exactly where a structured screen earns its place in the chart.

    Who should be screened for vitamin D deficiency?

    • Malabsorption. Across 25 observational studies and 5,826 patients with inflammatory bowel disease, active disease raised deficiency odds to 1.85, prior surgery to 1.61, biologic exposure to 1.78, and the Crohn’s phenotype to 1.38 relative to ulcerative colitis. Steroid exposure also carried 1.61. Short bowel, celiac disease and post-bariatric anatomy share the mechanism.
    • Ancestry and latitude. Non-Caucasian ancestry carried an odds ratio of 3.79 in that same analysis, larger than any disease variable. Keeping 97.5% of dark-skinned adults at high latitude above 50 nmol/L in winter required 66.8 µg daily, roughly 2,672 IU, well above standard intake tables.
    • Adiposity. Adipose tissue sequesters the molecule and lowers the circulating level, and BMI does not quantify the compartment responsible.
    • Fall risk. Not an indication to supplement, but a reason to document balance status before a dosing schedule is chosen, because the harm signal in the dosing literature is falls.

    How accurate is the vitamin D blood test?

    Two error sources precede interpretation. Restandardization moved the American prevalence below 50 nmol/L from 22% to 31%, and the methods authors estimated that a single patient’s apparent level could range from 20 to 35 ng/mL by method. In the Canadian biobank comparison, the immunoassay carried an overall negative bias of 5.5 nmol/L against mass spectrometry, limits of agreement -23.8 to 12.7. The bias was 4.0 nmol/L below the non-HDL cholesterol threshold and 10.2 above it, and assay standardization did not eliminate it.

    The consequence is directional. Dyslipidemic patients, the ones carrying insulin resistance and metaflammation, are biased toward a falsely low value, and the reference interval printed beside it was drawn from a largely indoor population. Recording the assay method with the value changes what a borderline number means and makes serial values comparable.

    Can vitamin D dosing increase falls?

    Trials that failed on benefit are informative on harm, and the harm concentrates in falls.

    • Annual bolus. In 2,256 older women given 500,000 IU once a year, the fall rate was 83.4 versus 72.7 per 100 person-years, a rate ratio of 1.15, and fractures rose with a rate ratio of 1.26, the excess concentrated in the first three months after dosing. Median baseline was 49 nmol/L; fewer than 3% were below 25. These women were largely replete.
    • Higher daily dose in fall-prone adults. Compared with 200 IU, 1000 IU or more yielded a hazard ratio of 1.87 for serious falls and 2.48 for falls requiring hospitalization, with no improvement in gait speed, grip strength, chair-stand performance or six-minute walk distance.
    • Sustained high dose. Over three years, 10,000 IU daily reduced radial volumetric density by 7.5 mg HA/cm3 against 400 IU. Serum levels peaked at 188 nmol/L at three months and declined to 144.4 on an unchanged dose, consistent with catabolic adaptation. Bone strength did not differ.

    For a practice, that moves fall prevention from a separate program into the vitamin D decision. A documented baseline from vestibular and balance testing, obtained before a schedule is set and repeated at reassessment, turns a trial signal into something observable in the individual patient. The pairing with cognition, which shares the same older population, is laid out in cognitive assessment and fall prevention.

    Building vitamin D screening into workflow

    An indication-driven order set is more defensible than either routine testing or none. One workable sequence:

    1. Flag indications at intake: bowel resection, inflammatory bowel disease, celiac disease, bariatric surgery, chronic steroid or biologic exposure, darker skin at northern latitude, obesity.
    2. Order the level with the metabolic blood work so the context from laboratory panels sits beside it, and record the assay method.
    3. Add bioimpedance body composition where adiposity is part of the indication.
    4. Document balance status before dosing and at reassessment.
    5. Document schedule, daily rather than bolus, and a stop point once the deficit is corrected.

    Measura [Cardiometabolic and Autonomic Health Analysis] measures and reports; the ordering physician interprets and manages. Protocolizing the screen is covered in standing orders for screening, and the documentation maps to the quality frameworks described in quality measures that cardiometabolic testing supports. The gastrointestinal patient who needs this screen often carries a second missed problem, addressed in screening IBD patients for spinal involvement. Full study data are in the Chapter 10 Deep Dive.

    Frequently asked questions

    Does the 2024 Endocrine Society guideline rule out vitamin D testing?

    No. It suggests against routine testing in populations without an established indication, and its supporting review found no trials of screening in either direction. Patients with malabsorption, bowel resection, bariatric anatomy or chronic steroid exposure sit outside that scope. The panel still names four groups for empiric supplementation and prefers daily dosing over intermittent high doses. Patient selection is summarized in selection criteria.

    Should immunoassay results be read differently in dyslipidemic patients?

    Consider the direction of the bias. Against mass spectrometry, the immunoassay under-read by 10.2 nmol/L above the non-HDL cholesterol threshold and 4.0 nmol/L below it, and standardization did not remove the interference. A borderline value in a patient with high lipids may exaggerate deficiency. Recording the method keeps serial values comparable. Report structure is described in interpreting the report.

    Is bolus vitamin D dosing appropriate in older adults?

    The trial evidence argues against it. A single annual 500,000 IU dose increased falls and fractures in older women who were largely replete, with the excess clustered after dosing, and the guideline prefers daily over intermittent high doses in adults over 50. A large dose raises fibroblast growth factor 23, which suppresses activation and accelerates catabolism. Falls documentation within the wellness visit is outlined in annual wellness visit integration.

    How does fall-risk assessment change vitamin D management?

    It identifies the population in which dosing harm was measured. In fall-prone older adults, 1000 IU daily or more carried a hazard ratio of 1.87 for serious falls against 200 IU. A documented balance baseline lets you detect deterioration after a schedule change instead of inferring it after an injury. Reporting for falls-related screening is covered in MIPS and quality reporting.

    Does correcting vitamin D treat inflammatory bowel disease?

    Not on current evidence. Mendelian randomization in the Copenhagen and UK Biobank cohorts yielded a hazard ratio of 0.98 for Crohn’s disease and 1.01 for colitis, arguing against a causal role. Deficiency in these patients tracks disease activity, surgery and malabsorption, so correction addresses a real deficit rather than the bowel disease. The broader case for measuring terrain is in clinical rationale.

    Why don’t doctors test vitamin D levels routinely?

    Because the 2024 Endocrine Society guideline recommends against routine testing of 25-hydroxyvitamin D in people without an established indication. Its supporting review screened 37,007 citations and found no trials of screening itself, so the advice reflects a test-and-treat strategy that was never trialed. Patients with malabsorption, prior bowel or bariatric surgery, darker skin at high latitude or adiposity sit outside that scope.

    What test is done to check vitamin D?

    A blood level of 25-hydroxyvitamin D. A common method is immunoassay; mass spectrometry is the reference. In a Canadian biobank comparison the immunoassay read 5.5 nmol/L low overall, and lower still in patients above the non-HDL cholesterol threshold. Recording which method was used, alongside the value, makes a borderline number interpretable and keeps serial results comparable.

    How often should vitamin D be checked?

    The evidence here sets no fixed interval. Order the level when an indication is flagged at intake, together with the metabolic blood work, and record the assay method so repeat values compare. Once a daily schedule starts, reassess with the balance measurement repeated, and document a stop point for when the deficit is corrected, so testing follows a clinical decision rather than a habit.

    Build an Indication Screen for Vitamin D

    Learn how the Measura protocol pairs laboratory panels with balance and body-composition testing, so indicated patients are documented before a dosing schedule is set.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., Rao, S. D., Scragg, R., Tayek, J. A., Valent, A. M., Walsh, J. M. E., & McCartney, C. R. (2024). Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 109(8), 1907–1947. https://doi.org/10.1210/clinem/dgae290
    • Shah, V. P., Nayfeh, T., Alsawaf, Y., Saadi, S., Farah, M., Zhu, Y., Firwana, M., Seisa, M., Wang, Z., Scragg, R., Kiely, M. E., Lips, P., Mitchell, D. M., Demay, M. B., Pittas, A. G., & Murad, M. H. (2024). A systematic review supporting the Endocrine Society clinical practice guidelines on vitamin D. The Journal of Clinical Endocrinology and Metabolism, 109(8), 1961-1974. https://doi.org/10.1210/clinem/dgae312
    • Shi, S., Feng, J., Zhou, L., Li, Y., & Shi, H. (2021). Risk factors for vitamin D deficiency in inflammatory bowel disease: A systematic review and meta-analysis. The Turkish Journal of Gastroenterology, 32(6), 508–518. https://doi.org/10.5152/tjg.2021.20614
    • Cashman, K. D., Kiely, M. E., Andersen, R., Grønborg, I. M., Tetens, I., Tripkovic, L., Lanham-New, S. A., Lamberg-Allardt, C., Adebayo, F. A., Gallagher, J. C., Smith, L. M., Sacheck, J. M., Huang, Q., Ng, K., Yuan, C., Giovannucci, E. L., Rajakumar, K., Patel, S., Vanstone, C. A., … Weiler, H. A. (2022). Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitude. European Journal of Nutrition, 61(2), 1015–1034. https://doi.org/10.1007/s00394-021-02699-6
    • Binkley, N., Dawson-Hughes, B., Durazo-Arvizu, R., Thamm, M., Tian, L., Merkel, J. M., Jones, J. C., Carter, G. D., & Sempos, C. T. (2017). Vitamin D measurement standardization: The way out of the chaos. The Journal of Steroid Biochemistry and Molecular Biology, 173, 117–121. https://doi.org/10.1016/j.jsbmb.2016.12.002
    • Weiler, H. A., Bielecki, A., Fu, W., Demonty, I., & Brooks, S. P. J. (2024). Cholesterol interference in the assessment of vitamin D status: A Canadian Health Measures Survey biobank project. The Journal of Nutrition, 154(5), 1676–1685. https://doi.org/10.1016/j.tjnut.2024.04.003
    • Sanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., & Nicholson, G. C. (2010). Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA, 303(18), 1815–1822. https://doi.org/10.1001/jama.2010.594
    • Appel, L. J., Michos, E. D., Mitchell, C. M., Blackford, A. L., Sternberg, A. L., Miller, E. R., Juraschek, S. P., Schrack, J. A., Szanton, S. L., Charleston, J., Minotti, M., Baksh, S. N., Christenson, R. H., Shade, D. M., Shiferaw, W. F., Walston, J. D., Guralnik, J. M., Cai, T., & Tonascia, J. (2021). The effects of four doses of vitamin D supplements on falls in older adults: A response-adaptive, randomized clinical trial. Annals of Internal Medicine, 174(2), 145–156. https://doi.org/10.7326/M20-3812
    • Burt, L. A., Billington, E. O., Rose, M. S., Raymond, D. A., Hanley, D. A., & Boyd, S. K. (2019). Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: A randomized clinical trial. JAMA, 322(8), 736–745. https://doi.org/10.1001/jama.2019.11889
    • Lund-Nielsen, J., Vedel-Krogh, S., Kobylecki, C. J., Brynskov, J., Afzal, S., & Nordestgaard, B. G. (2018). Vitamin D and inflammatory bowel disease: Mendelian randomization analyses in the Copenhagen studies and UK Biobank. The Journal of Clinical Endocrinology and Metabolism, 103(9), 3267–3277. https://doi.org/10.1210/jc.2018-00250

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 9 title card of The Angry Gut reading Your Gut Is Suffocating.

    Erectile Dysfunction Cardiovascular Risk: A Sentinel in Primary Care

    Your Gut Is Suffocating | The Angry Gut, Chapter 9

    Erectile Dysfunction Cardiovascular Risk: A Sentinel in Primary Care

    Erectile dysfunction is an early marker of cardiovascular risk: across 14 cohort studies, men with it had a 44% higher hazard of cardiovascular events and a 62% higher hazard of myocardial infarction, and in men with both conditions it preceded coronary symptoms by a mean of 24 months.

    A symptom reported without prompting, predicting cardiovascular death at a magnitude comparable to diabetes, usually closes the visit with a prescription instead of opening a vascular assessment.

    Erectile dysfunction cardiovascular risk is among the better-quantified sentinel associations in vascular medicine and one of the least acted upon. The patient at the center of Chapter 9 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, had postprandial abdominal pain, atrial fibrillation, hypertension on three agents and erectile dysfunction reported to a different physician, and four endoscopies preceded any arterial imaging. The video above, Your Gut Is Suffocating, frames that presentation as one endothelial failure reported by three organs. For a screening practice the questions are who to measure, what functional testing shows, and what a finding changes.

    How much does erectile dysfunction raise cardiovascular risk?

    Vlachopoulos and colleagues pooled 14 cohort studies with 92,757 participants and found a hazard of 1.44 (95% CI 1.27-1.63) for total cardiovascular events in men with erectile dysfunction, and 1.62 (95% CI 1.34-1.96) for myocardial infarction. A later synthesis of 25 studies and 154,794 people estimated excess risk of 43% for cardiovascular disease, 59% for coronary disease, 34% for stroke and 33% for all-cause death, strongest in men over 55 and where the symptom was under seven years old. In the COBRA cohort of men with chronic coronary syndrome and both conditions, sexual dysfunction preceded coronary symptoms in 93%, by a mean of 24 months.

    A nationally representative US sample adds durability: 4,110 men followed a median 16.3 years, with erectile dysfunction predicting cardiovascular death at 1.57, a magnitude the authors placed alongside diabetes, hypertension and stroke. Exposure was a single survey item, which should dilute rather than inflate the estimate. In a European community cohort of 1,788 men aged 40 to 79, erectile dysfunction predicted death at 1.40 (95% CI 1.13-1.74) independent of total and unbound testosterone and of estradiol, while low libido did not. The vascular symptom carried the signal; the hormonal one did not.

    Why is erectile dysfunction an early sign of heart disease?

    Endothelial nitric oxide synthase, deprived of cofactor and substrate, uncouples and generates superoxide, described as a major driver of endothelial dysfunction and atherogenesis. Oxidized LDL acting through LOX-1 recruits NADPH oxidase toward the same end; in 4,658 people followed 19.5 years, the top tertile of soluble LOX-1 predicted first myocardial infarction at HR 1.76 (1.40-2.21). Penile arteries are small and nitric oxide dependent, so they declare failure early.

    The splanchnic bed is the less obvious reporter. Mesenteric flow rises 30-150% after a meal, and significant mesenteric stenosis appears in 6-29% of post-mortem and ultrasound series, possibly 67% of people over 80. The European guideline names the expectation of a cachectic patient as a diagnostic pitfall. Inflammatory bowel disease shows the systemic version: across 41 studies, flow-mediated dilation was reduced (effect size 0.73) and pulse wave velocity increased (0.76), with heterogeneity high enough to read as direction rather than magnitude.

    Two exposures sit outside the medication list. Habitual antiseptic mouthwash suppresses the oral bacteria that reduce dietary nitrate to nitrite; in 15 treated hypertensives three days raised systolic pressure 2.3 mm Hg, and in a cohort twice-daily use carried an incidence rate ratio of 1.85 for new hypertension. A null in 17 healthy young women is real and population-specific. Degraded frying oil is the second: in 538 households, more degraded kitchen oil tracked hypertension after adjustment, while the single randomized one-meal trial enrolled 19 healthy men and so excluded the failing endothelium. Exposure concentrates where fryer oil is changed least often, among patients with the fewest food options.

    Who to measure

    • Men reporting erectile dysfunction without a documented cardiovascular risk assessment, particularly those over 55 or with symptoms of recent onset.
    • Erectile dysfunction accompanied by hypertension, dysglycemia, atrial fibrillation or tobacco use.
    • Postprandial abdominal pain, food avoidance or weight loss in a patient with vascular risk factors, in parallel with mesenteric imaging.
    • Inflammatory bowel disease with cardiometabolic risk factors.
    • Treated hypertension that remains difficult to control in a habitual antiseptic rinse user.

    What functional testing shows, and what it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] provides functional vascular and metabolic measurement, not anatomic imaging. Arterial stiffness and endothelial function assesses large-artery rigidity and endothelium-dependent dilatory capacity, the systemic correlate of the nitric oxide failure described above. Pulse volume recording captures segmental limb volume waveforms, and the ankle-brachial index, with toe-brachial measurement where vessels are noncompressible, characterizes lower-extremity arterial disease that often travels with the same risk profile. Laboratory panels define glycemic, insulin and lipid status.

    Measura does not image mesenteric vessels. Suspected chronic mesenteric ischemia requires vascular imaging arranged separately, and a normal limb or stiffness study does not exclude it. Nor is there a blood shortcut: 75 studies of 9,914 patients found no biomarker reaching conclusive accuracy for intestinal ischemia. Findings return to the ordering physician.

    What a finding changes

    An abnormal endothelial or stiffness result in a man presenting with erectile dysfunction converts a urologic encounter into a documented cardiovascular risk assessment. The PRINCETON IV consensus describes erectile dysfunction as a risk marker and enhancer and advises considering coronary calcium scoring in men at intermediate risk; in MESA, coronary calcium above 100 predicted subsequent erectile dysfunction at an odds ratio of 1.43. A measured finding supports that evaluation, informs risk-factor intensification by the treating physician and establishes a baseline for reassessment. It argues nothing against phosphodiesterase inhibitor therapy, which works; the concern is the visit that ends when the prescription is written.

    Dr. Padda is direct that his own training ran the other way: route each complaint to the organ that reports it, erection to urology, meal pain to gastroenterology, pressure to cardiology. The correction is procedural rather than heroic. Make the sentinel symptom a trigger.

    Workflow and documentation

    A standing order keyed to an erectile dysfunction diagnosis or a phosphodiesterase inhibitor prescription makes the screen independent of who is in clinic. The annual wellness visit review of systems is a practical place to ask the question most men will not volunteer, and results belong in structured fields as described in getting results into the record. The patient-facing version is the patient article on endothelial dysfunction, the full appraisal sits on the Chapter 9 book companion page, and the dietary fat and supplement side is in fish oil, atrial fibrillation and screening.

    Frequently asked questions

    Is erectile dysfunction an independent predictor of cardiovascular events?

    Pooled cohort data support it. Across 14 studies, erectile dysfunction predicted cardiovascular events at 1.44 and myocardial infarction at 1.62, and a larger synthesis of 25 studies found a 43% excess in cardiovascular disease. In US men followed 16.3 years it predicted cardiovascular death at 1.57, comparable in magnitude to diabetes. See the clinical rationale for the protocol.

    Does low testosterone explain the association?

    Apparently not. In 1,788 community-dwelling European men followed a mean 12.6 years, erectile dysfunction predicted mortality at 1.40 after adjustment for total testosterone, unbound testosterone and estradiol, while low libido did not predict it. The endpoint was all-cause death, so it should not be quoted as a cardiac figure, but it points to a vascular rather than hormonal mechanism. See guidance on interpreting the report.

    Can noninvasive vascular testing exclude chronic mesenteric ischemia?

    No. Limb pressures, waveforms and arterial stiffness describe the systemic vascular phenotype but do not image the celiac or mesenteric arteries. Postprandial pain with food avoidance warrants dedicated mesenteric imaging, and a normal body weight should not delay it, a pitfall the European guideline names explicitly. No blood biomarker has reached conclusive diagnostic accuracy either. See specialty applications by practice type.

    Should antiseptic mouthwash use be part of the vascular history?

    It is a reasonable question in treated hypertensives. Three days of antibacterial rinse raised systolic pressure 2.3 mm Hg in 15 treated patients, and twice-daily use tracked with incident hypertension in a cohort. A pooled analysis of chlorhexidine trials judged the average change small, and no trial has withdrawn long-term habitual use. See the selection criteria.

    How should an erectile dysfunction-triggered assessment be documented?

    Record the sentinel symptom as the indication, the cardiovascular risk factors reviewed, the vascular and metabolic measurements obtained, and the resulting management decision in structured fields. That documents a risk assessment rather than a prescription renewal and supports cardiovascular and diabetes quality documentation where the practice reports those measures. See MIPS and quality reporting guidance.

    How do you know if erectile dysfunction is heart related?

    The symptom alone cannot tell you, which is why it should start a measurement rather than end the visit. The excess risk is strongest in men over 55 and where the symptom is under seven years old, and men who also have high blood pressure, high blood sugar, atrial fibrillation or tobacco use are the ones to measure first. Arterial stiffness and endothelial function testing shows whether the vessel lining is failing, and findings return to the ordering physician.

    How long before heart problems does erectile dysfunction appear?

    In men with chronic coronary disease who had both conditions, the erection problem came first in 93% of them, by a mean of 24 months. That lead time is the opening. Penile arteries are small and depend on nitric oxide, so they declare failure before the coronary arteries cause chest symptoms. Two years is enough time to measure the vessels and act on what the measurement shows.

    Is a prescription enough for erectile dysfunction?

    The pill works, and nothing here argues against it. The problem is the visit that ends when the prescription is written. A symptom that predicts cardiovascular death at a magnitude comparable to diabetes deserves a documented cardiovascular risk assessment. A standing order tied to an erectile dysfunction diagnosis or a phosphodiesterase inhibitor prescription makes that assessment happen no matter who is in clinic that day.

    See how the protocol fits your practice

    Learn how Measura vascular and metabolic testing can be triggered by sentinel symptoms such as erectile dysfunction, from standing orders to structured reporting.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Vlachopoulos, C. V., Terentes-Printzios, D. G., Ioakeimidis, N. K., Aznaouridis, K. A., & Stefanadis, C. I. (2013). Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: A systematic review and meta-analysis of cohort studies. Circulation: Cardiovascular Quality and Outcomes, 6(1), 99-109. https://doi.org/10.1161/CIRCOUTCOMES.112.966903
    • Montorsi, P., Ravagnani, P. M., Galli, S., Rotatori, F., Veglia, F., Briganti, A., Salonia, A., Dehò, F., Rigatti, P., Montorsi, F., & Fiorentini, C. (2006). Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. European Heart Journal, 27(22), 2632-2639. https://doi.org/10.1093/eurheartj/ehl142
    • Zhao, B., Hong, Z., Wei, Y., Yu, D., Xu, J., & Zhang, W. (2019). Erectile dysfunction predicts cardiovascular events as an independent risk factor: A systematic review and meta-analysis. The Journal of Sexual Medicine, 16(7), 1005-1017. https://doi.org/10.1016/j.jsxm.2019.04.004
    • Antonio, L., Wu, F. C. W., Moors, H., Matheï, C., Huhtaniemi, I. T., Rastrelli, G., Dejaeger, M., O’Neill, T. W., Pye, S. R., Forti, G., Maggi, M., Casanueva, F. F., Slowikowska-Hilczer, J., Punab, M., Tournoy, J., & Vanderschueren, D. (2022). Erectile dysfunction predicts mortality in middle-aged and older men independent of their sex steroid status. Age and Ageing, 51(4), afac094. https://doi.org/10.1093/ageing/afac094
    • Bhattacharyya, S., Miller, L. E., Rojanasarot, S., & Patel, D. P. (2025). Association of erectile dysfunction with all-cause and cardiovascular mortality in US men: Findings from NHANES 2001-2004 with 16-year follow-up. International Journal of Impotence Research. Advance online publication. https://doi.org/10.1038/s41443-025-01218-z
    • Schiopu, A., Björkbacka, H., Narasimhan, G., Loong, B. J., Engström, G., Melander, O., Orho-Melander, M., & Nilsson, J. (2023). Elevated soluble LOX-1 predicts risk of first-time myocardial infarction. Annals of Medicine, 55(2), 2296552. https://doi.org/10.1080/07853890.2023.2296552
    • Terlouw, L. G., Moelker, A., Abrahamsen, J., Acosta, S., Bakker, O. J., Baumgartner, I., Boyer, L., Corcos, O., van Dijk, L. J., Duran, M., Geelkerken, R. H., Illuminati, G., Jackson, R. W., Kärkkäinen, J. M., Kolkman, J. J., Lönn, L., Mazzei, M. A., Nuzzo, A., Pecoraro, F., … Bruno, M. J. (2020). European guidelines on chronic mesenteric ischaemia – joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. United European Gastroenterology Journal, 8(4), 371-395. https://doi.org/10.1177/2050640620916681
    • Wu, H., Xu, M., Hao, H., Hill, M. A., Xu, C., & Liu, Z. (2022). Endothelial dysfunction and arterial stiffness in patients with inflammatory bowel disease: A systematic review and meta-analysis. Journal of Clinical Medicine, 11(11), 3179. https://doi.org/10.3390/jcm11113179
    • Rosen, R. C., Miner, M., Burnett, A. L., Blaha, M. J., Ganz, P., Goldstein, I., Kim, N., Kohler, T., Lue, T., McVary, K., Mulhall, J., Parish, S. J., Sadeghi-Nejad, H., Sadovsky, R., Sharlip, I., & Kloner, R. A. (2024). Proceedings of PRINCETON IV: PDE5 inhibitors and cardiac health symposium. Sexual Medicine Reviews, 12(4), 681-709. https://doi.org/10.1093/sxmrev/qeae043
    • Bondonno, C. P., Liu, A. H., Croft, K. D., Considine, M. J., Puddey, I. B., Woodman, R. J., & Hodgson, J. M. (2015). Antibacterial mouthwash blunts oral nitrate reduction and increases blood pressure in treated hypertensive men and women. American Journal of Hypertension, 28(5), 572-575. https://doi.org/10.1093/ajh/hpu192

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 8 title card of The Angry Gut reading Your Gut Wall Is What You Fried Last Week.

    Fish Oil and Atrial Fibrillation: Measuring Before the Capsule

    Your Gut Wall Is What You Fried Last Week | The Angry Gut, Chapter 8

    Fish Oil and Atrial Fibrillation: Measuring Before the Capsule

    Fish oil raises atrial fibrillation risk in a dose-related way: across seven pooled cardiovascular trials, the hazard ratio was 1.12 at 1 g daily or below and 1.49 above 1 g. Omega-3 use above 1 g daily belongs in the vascular history and in the selection rule for metabolic and vascular screening.

    Patients with gut symptoms and metabolic risk increasingly arrive self-dosed on omega-3 capsules. The trial record argues for measuring the terrain before endorsing the capsule.

    The fish oil atrial fibrillation association is dose-related in pooled cardiovascular trials, and it is seldom weighed when a patient with abdominal symptoms or metabolic risk starts a high-dose capsule unprompted. Playing above is Your Gut Wall Is What You Fried Last Week, drawn from Chapter 8 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, which argues that the intestinal epithelium is rebuilt from dietary fat every few days and that structural lipids are a food question. For a screening practice the questions are narrower: what the fat exposure actually is, what the supplement adds to risk, and which measurements change management.

    Does fish oil cause atrial fibrillation, and at what dose?

    Gencer and colleagues pooled seven cardiovascular outcome trials covering 81,210 patients, mean age 65, with average follow-up of 4.9 years. Incident atrial fibrillation carried a hazard ratio of 1.12 (95% CI 1.03-1.22) at doses of 1 g daily or below, 1.49 above 1 g, and 1.11 for each additional gram. An independent meta-analysis of 15 trials returned RR 1.25 (95% CI 1.10 to 1.41), alongside modest reductions in major cardiovascular events (RR 0.95) and myocardial infarction (RR 0.90), with no overall excess of bleeding. The inflammatory bowel disease trials used 2 to 4 g daily, inside the higher band.

    The supplement list therefore belongs in the vascular history. Rhythm assessment itself is electrocardiographic and sits outside a Measura protocol; what measurement adds is the metabolic and vascular context in which that rhythm risk is being accepted.

    Does fish oil help Crohn’s disease or ulcerative colitis?

    Enthusiasm traces to a 1996 trial of enteric-coated fish oil in Crohn’s disease, in which 11 of 39 treated patients relapsed against 27 of 39 controls. EPIC-1 and EPIC-2 then randomized 738 patients at 98 centers to 4 g daily as monotherapy. One-year relapse was 31.6% versus 35.7% in the first trial and 47.8% versus 48.8% in the second. Cochrane pooling of six trials gave RR 0.77; restricted to the two trials at low risk of bias, the estimate became 0.88 (95% CI 0.74 to 1.05). The ulcerative colitis review holds three trials and 138 patients, RR 1.02, an interval too wide to interpret. Omega-3 raised diarrhea (RR 1.36) and upper gastrointestinal symptoms (RR 1.65).

    Design limits what those nulls can say. The trials enrolled a single disease and excluded the patient who presents with insulin resistance, hypertension, disordered sleep and a long medication list. For that patient the practice relies on mechanism and states the tier plainly: a food-based recommendation about membrane composition, not a trial-tier claim about a capsule.

    Exposure misclassification in the fat literature

    Much of the reassurance about dietary polyunsaturated fat, and much of the alarm, rests on circulating biomarkers that index an intact fatty acid, usually sampled once. That design cannot distinguish fresh oil from oil degraded by storage, heat and repeated use, which is how a large share of commercial fried fat reaches patients. The practice does not describe seed oils as toxic. It treats unmeasured oxidative degradation as a classification error in the exposure variable, one that biases toward the null for the degraded fraction.

    Dairy fat carries the mirror-image problem. Plasma pentadecanoic acid tracked lower incident type 2 diabetes across 16 prospective cohorts (HR 0.80, 95% CI 0.73-0.87), yet it is the standard biomarker of dairy intake and cannot identify the food source. Assays add a second layer: resolvin D1 measures near 30 pg/ml by mass spectrometry and above 2,000 pg/ml by commercial ELISA, a gap attributed to cross-reactivity. Interpret any lipid-derived marker by its method before its magnitude.

    Who to measure

    A selection rule keyed to exposure rather than to gastrointestinal symptoms alone:

    • Omega-3 supplementation above 1 g daily, particularly when self-initiated for gut or joint complaints.
    • Chronic abdominal symptoms with metabolic features such as central adiposity, dysglycemia or elevated triglycerides.
    • A dietary history dominated by fried or commercially prepared food.
    • Hypertension or established vascular disease, where rhythm and vascular risk compound.
    • Normal body weight with metabolic abnormalities, a phenotype BMI conceals.

    Measura [Cardiometabolic and Autonomic Health Analysis] offers three measurements that fit this patient. Laboratory panels define glycemic and insulin status and the triglyceride and HDL pattern. Arterial stiffness and endothelial function assesses large-artery rigidity and the capacity of the endothelium to dilate. Bioimpedance body composition separates lean and fat compartments. Measura does not quantify tissue fatty acid composition, does not diagnose inflammatory bowel disease, and returns findings to the ordering physician.

    What a finding changes

    An abnormal vascular or metabolic result does not settle whether a given patient should take fish oil. It moves the decision from a population estimate to the individual: whether a high-dose capsule is supported by an indication a trial has actually tested, whether the dietary fat pattern warrants structured change, and whether separate rhythm evaluation is indicated. It also establishes a baseline. An epithelium that turns over in days responds to sustained dietary change, and the patient described in Chapter 8 improved over about five months with no way to credit any single change. Remeasurement documents whether the terrain moved.

    Dr. Padda is candid that he once held the opposite view. As a strict vegetarian he cooked in the oils the guidelines endorsed and counseled patients accordingly, and the correction came from pathology rather than from a trial. The same discipline applies to the capsule: if the indication has not been tested, measure before endorsing it.

    Workflow and documentation

    A standing order keyed to omega-3 doses above 1 g on the medication list makes the screen reproducible. The medication review in an annual wellness visit is a natural trigger point, and results belong in structured fields covered by getting results into the record. The patient-facing account is the patient article on seed oils and testing, the full study appraisal is on the Chapter 8 book companion page, and the vascular follow-on, endothelial nitric oxide and the erectile sentinel, is in erectile dysfunction as a cardiovascular risk marker.

    Frequently asked questions

    Does fish oil raise atrial fibrillation risk at low doses?

    In the pooled cardiovascular outcome trials, the hazard ratio was 1.12 even at 1 g daily or less, rising to 1.49 above 1 g and 1.11 per additional gram. Mean age was 65. The independent 15-trial meta-analysis found RR 1.25 while also reporting fewer major cardiovascular events and no overall rise in bleeding. The risk is dose-related rather than threshold-bound. Clinical rationale.

    Is fish oil supported for maintenance of remission in Crohn’s disease?

    Not by the larger trials. EPIC-1 and EPIC-2 enrolled 738 patients and found no meaningful difference in one-year relapse, and the Cochrane estimate lost significance when limited to low-risk-of-bias trials. Those trials excluded multimorbid patients and forbade concurrent therapy, which limits generalization but does not rescue the capsule. Therapeutic decisions remain with the treating gastroenterologist. Specialty applications.

    Can a circulating fatty acid level stand in for dietary fat exposure?

    Only partly. Circulating biomarkers index the intact fatty acid, usually from a single sample, and cannot register oil degraded before ingestion. Dairy biomarkers cannot identify food source. Treat such values as one input to a dietary history rather than as the exposure itself, and interpret any lipid mediator result by assay method first. Interpreting the report.

    Which patients with gut symptoms warrant vascular and metabolic testing?

    Prioritize those combining chronic abdominal symptoms with central adiposity, dysglycemia, elevated triglycerides, hypertension or high-dose omega-3 use. A normal body weight does not exclude the metabolic phenotype. Laboratory panels, arterial stiffness and endothelial function, and body composition describe the shared terrain without substituting for the gastrointestinal workup. Selection criteria.

    How should the assessment be documented?

    Record the trigger, the supplement dose and indication, the measurements obtained and the resulting decision in structured fields. That turns an unexamined supplement into a documented reassessment with a baseline for comparison, and it supports cardiovascular and diabetes-related quality documentation where the practice reports them. Quality measures that cardiometabolic testing supports.

    Who should be careful with high-dose fish oil?

    Anyone taking more than 1 g of omega-3 a day, especially when they started it on their own for gut or joint complaints. The concern grows with high blood pressure or established vascular disease, where rhythm and vascular risk compound, and with metabolic warning signs such as belly fat, high blood sugar or high triglycerides. These are the patients to measure first: laboratory panels, arterial stiffness and endothelial function, and body composition.

    Why isn’t fish oil recommended for everyone?

    Because the benefit in the trials is small and the tradeoffs are real. In a 15-trial analysis, fish oil trimmed major cardiovascular events only slightly (RR 0.95) while atrial fibrillation rose (RR 1.25). In Crohn’s disease, the larger trials found no meaningful drop in relapse, and the capsules raised diarrhea and upper stomach symptoms. When the reason for taking it has not been tested, measure before endorsing the capsule.

    See how the protocol fits your practice

    Learn how Measura testing fits a screening workflow for patients on high-dose supplements or with gut symptoms and metabolic risk, from standing orders to reporting.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Gencer, B., Djousse, L., Al-Ramady, O. T., Cook, N. R., Manson, J. E., & Albert, C. M. (2021). Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: A systematic review and meta-analysis. Circulation, 144(25), 1981–1990. https://doi.org/10.1161/CIRCULATIONAHA.121.055654
    • Yan, J., Liu, M., Yang, D., Zhang, Y., & An, F. (2024). Efficacy and safety of omega-3 fatty acids in the prevention of cardiovascular disease: A systematic review and meta-analysis. Cardiovascular Drugs and Therapy, 38(4), 799-817. https://doi.org/10.1007/s10557-022-07379-z
    • Belluzzi, A., Brignola, C., Campieri, M., Pera, A., Boschi, S., & Miglioli, M. (1996). Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. The New England Journal of Medicine, 334(24), 1557–1560. https://doi.org/10.1056/NEJM199606133342401
    • Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S., D’Haens, G., Bradette, M., Cohen, A., Dallaire, C., Ponich, T. P., McDonald, J. W. D., Hébuterne, X., Paré, P., Klvana, P., Niv, Y., Ardizzone, S., Alexeeva, O., Rostom, A., Kiudelis, G., Spleiss, J., … Greenberg, G. R. (2008). Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA, 299(14), 1690–1697. https://doi.org/10.1001/jama.299.14.1690
    • Lev-Tzion, R., Griffiths, A. M., Leder, O., & Turner, D. (2014). Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 2014(2), CD006320. https://doi.org/10.1002/14651858.CD006320.pub4
    • Turner, D., Steinhart, A. H., & Griffiths, A. M. (2007). Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, CD006443. https://doi.org/10.1002/14651858.CD006443.pub2
    • Imamura, F., Fretts, A., Marklund, M., Ardisson Korat, A. V., Yang, W.-S., Lankinen, M., Qureshi, W., Helmer, C., Chen, T.-A., Wong, K., Bassett, J. K., Murphy, R., Tintle, N., Yu, C. I., Brouwer, I. A., Chien, K.-L., Frazier-Wood, A. C., Del Gobbo, L. C., Djoussé, L., … Mozaffarian, D. (2018). Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS Medicine, 15(10), e1002670. https://doi.org/10.1371/journal.pmed.1002670
    • Schebb, N. H., Kühn, H., Kahnt, A. S., Rund, K. M., O’Donnell, V. B., Flamand, N., Peters-Golden, M., Jakobsson, P.-J., Weylandt, K. H., Rohwer, N., Murphy, R. C., Geisslinger, G., FitzGerald, G. A., Hanson, J., Dahlgren, C., Alnouri, M. W., Offermanns, S., & Steinhilber, D. (2022). Formation, signaling and occurrence of specialized pro-resolving lipid mediators — what is the evidence so far? Frontiers in Pharmacology, 13, 838782. https://doi.org/10.3389/fphar.2022.838782

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card Collagen Is the Wall, Not the Paint, The Angry Gut, Chapter 7

    Orthostatic Intolerance in Hypermobility: A Primary Care Screen

    Collagen Is the Wall, Not the Paint | The Angry Gut, Chapter 7

    Orthostatic Intolerance in Hypermobility: A Primary Care Screen

    Orthostatic intolerance affects 35.9% of patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder in pooled data, so every hypermobile patient warrants a screen. Autonomic nervous system testing and cardiac autonomic reflex tests measure it, with results returned to the ordering physician.

    Hypermobile patients arrive with normal GI workups and decades of symptoms. The orthostatic and autonomic burden that travels with the diagnosis is common, measurable and usually undocumented.

    Orthostatic intolerance is one of the most common extra-intestinal findings in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder, and one of the least often measured in practice. These patients usually arrive through a gastroenterology or rheumatology door with a normal workup and a long history. The collagen biology is laid out in Collagen Is the Wall, Not the Paint, a chapter video for The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes). For the treating physician the useful questions are operational: which comorbidities to screen for, which red flags change the referral, and how autonomic, balance and body-composition measurement fits a primary care workflow.

    What conditions travel with hypermobility beyond the gut?

    A 2026 meta-analysis pooled gastrointestinal and extra-intestinal data in this population. Chronic gut symptoms carried an odds ratio of 4.29 against controls; nearly two thirds, 65.3%, had one or more chronic gut complaints, and 44.2% fulfilled diagnostic criteria for a disorder of gut-brain interaction. The leading gut findings were upper tract: reflux at 41.3%, heartburn at 34.7%, functional dysphagia at 34.2%.

    The extra-intestinal tail is where screening matters. Pooled prevalence ran 49% for chronic fatigue, 35.9% for orthostatic intolerance, 38.2% for migraine and 27.9% for fibromyalgia. Postural tachycardia pooled at 21.9%, but its interval of 5.2% to 59.1% makes the point estimate nearly useless for counseling. A global survey adds self-reported dysautonomia in 71.4%, chronic pain in 98.9%, a mean of 24 comorbid conditions and a mean diagnostic delay of 22.1 years. Survey data are self-selected, but a 22-year delay describes a care model, not a rare disease.

    What the motility data argue

    If lax collagen simply produced a lax bowel, manometry should show it. In 239 consecutive symptomatic patients undergoing antroduodenal manometry, 50 with hypermobility and 189 without, overall dysmotility and delayed gastric emptying did not differ, and enteric dysmotility turned up in 13% of hypermobile patients versus 34% of the others (p = 0.006). It is a single-unit research letter without a healthy comparison group. It still shifts the question. When the bowel moves normally and the patient remains symptomatic, the autonomic and orthostatic burden deserves a measurement before another GI study is ordered.

    My own error belongs here. I used to think of the intestinal lining as a construction site: deliver the protein and the wall goes up. The pediatric enteropathy trials, where feeding barely moved biomarkers or growth, proved that model incomplete. Raw material is necessary, and a lining under sustained attack, the first brain running on metaflammation, does not rebuild on supply alone.

    Red flags that change the referral

    • Vascular features. Vascular Ehlers-Danlos arises from a type III procollagen defect. In the classic cohort, bowel rupture accounted for about a quarter of complications, a quarter of patients had a first complication by age 20, and median survival was 48 years. Hypermobility with arterial or bowel events is not a primary care screening problem.
    • New malabsorption with a medication change. In collagenous sprue, where drug exposure was documented, 30 of 38 cases involved a medication tied to sprue-like injury, most often an angiotensin receptor blocker, and 37 of 50 improved on repeat biopsy. Read the medication list before labeling a small-bowel finding idiopathic.
    • A casual supplement plan in a sick patient. Among 1,223 ICU patients with multiorgan failure randomized in a glutamine trial, mortality at 28 days was 32.4% with glutamine and 27.2% without. That signal belongs to intensive care, but it argues against treating amino acid products as harmless in unwell patients.

    How is orthostatic intolerance measured, and what does each finding change?

    Measura [Cardiometabolic and Autonomic Health Analysis] has no connective-tissue assay and does not diagnose hypermobility disorders or postural tachycardia. It measures the regulatory and compositional consequences, with results returned to the ordering physician.

    • Autonomic nervous system testing and cardiac autonomic reflex tests document heart rate and blood pressure responses to standardized maneuvers, including postural change. An abnormal response supports referral and orthostatic counseling; a normal one redirects the workup.
    • Heart rate variability gives a repeatable index of autonomic balance for follow-up.
    • Vestibular and balance testing converts symptomatic orthostasis into a documented fall-risk finding.
    • Bioimpedance body composition quantifies the muscle compartment. In a review of randomized trials of collagen hydrolysate, muscle outcomes were inconsistent and mostly positive only with exercise, so a low lean mass argues for loading and adequate protein rather than a powder.

    Pair the measurements with a dietary protein estimate. The bowel-rest data are the human anchor: 14 days of parenteral feeding thinned the mucosa from 645 to 512 microns, and permeability lagged behind structural recovery after refeeding. Isolation, poor dentition and low appetite remove protein quietly, and none of them appears on a panel.

    Documentation and workflow

    Hypermobile patients accumulate referrals without a coordinating record. A standing order can attach an orthostatic symptom screen, autonomic testing and balance testing to a documented hypermobility diagnosis or a chronic unexplained upper-GI complaint with a normal structural workup. Fall-risk and functional findings belong in the annual wellness visit, and the pairing with falls work is described in cognitive assessment and fall prevention. Where results enter the chart is covered in getting results into the record. The full evidence file sits in the companion deep dive for The Angry Gut, and the patient explanation is EDS and POTS for patients. For the gastric absorption side, see intrinsic factor antibody screening.

    Frequently asked questions

    Which hypermobile patients should be screened for orthostatic intolerance?

    Pooled prevalence of orthostatic intolerance is 35.9% in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder, high enough to justify asking every patient with a documented diagnosis. Prioritize those with chronic fatigue, presyncope, migraine, or persistent upper-GI symptoms despite a normal structural workup, and those reporting falls or near-falls. Review the selection criteria.

    How reliable is the pooled POTS prevalence in hypermobility?

    Not very. Postural tachycardia pooled at 21.9%, but the interval ran from 5.2% to 59.1%, which makes the point estimate close to useless for counseling an individual patient. Survey figures such as 71.4% dysautonomia are self-reported. The practical answer is to measure autonomic responses in the patient in front of you rather than rely on a population rate. See guidance on interpreting the report.

    Does gastrointestinal dysmotility explain gut symptoms in hypermobile patients?

    Less often than expected. In a manometry series of 239 symptomatic patients, enteric dysmotility appeared in 13% of hypermobile patients versus 34% of the rest, with no difference in delayed gastric emptying. The dominant complaints are reflux, heartburn and functional dysphagia. That pattern argues for evaluating autonomic and orthostatic contributors before repeating motility studies. Read about specialty applications.

    When should hypermobility prompt concern for vascular Ehlers-Danlos syndrome?

    When there is a history of arterial, bowel or organ rupture, or a family history of it. In the classic vascular cohort, bowel rupture made up about a quarter of complications, a quarter of patients had a first complication by age 20, and median survival was 48 years. Those patients need specialist and genetic evaluation, not a primary care screening pathway. Read the clinical rationale.

    Can Measura results substitute for a POTS or connective-tissue diagnosis?

    No. Measura does not assess collagen and does not diagnose. Autonomic, heart rate variability, balance and body composition results give the treating physician objective data on regulation, fall risk and muscle, which support referral decisions, counseling and follow-up. Diagnosis remains a clinical judgment made with the history, examination and any specialist testing. See more physician questions.

    How is orthostatic intolerance tested in hypermobile patients?

    Autonomic nervous system testing and cardiac autonomic reflex tests document heart rate and blood pressure responses to standardized maneuvers, including postural change. An abnormal response supports referral and orthostatic counseling; a normal one redirects the workup. Heart rate variability gives a repeatable index for follow-up, and vestibular and balance testing turns symptomatic orthostasis into a documented fall-risk finding, with results returned to the ordering physician.

    What is the difference between POTS and orthostatic intolerance in hypermobility?

    Orthostatic intolerance is the broader complaint of symptoms on standing, pooled at 35.9% in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder. Postural tachycardia is one pattern within it, pooled at 21.9% with an interval of 5.2% to 59.1%. Because the population rates are this imprecise, recording each patient’s own heart rate and blood pressure response to posture is what separates the patterns.

    Is orthostatic intolerance dangerous in hypermobile patients?

    The routine danger is falls. Symptomatic orthostasis in a hypermobile patient is a fall-risk finding that belongs in the annual wellness visit, and balance testing documents it. The dangerous exception is vascular Ehlers-Danlos syndrome: hypermobility with a history of arterial, bowel or organ rupture needs specialist and genetic evaluation rather than a primary care screening pathway.

    Add autonomic measurement to the hypermobility workup

    Learn how the Measura protocol fits autonomic, balance and body composition testing into a practice’s screening and referral workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Kulin, D., Holtmann, G., Fairlie, T., Staller, K., Nurko, S., Keefer, L., Drossman, D. A., Jones, M. P., Talley, N. J., & Ford, A. C. (2026). Meta-analysis: Chronic gastrointestinal symptoms and comorbidities in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Alimentary Pharmacology & Therapeutics, 64(5), 574–589. https://doi.org/10.1111/apt.70856
    • Daylor, V., Griggs, M., Weintraub, A., Byrd, R., Petrucci, T., Huff, M., Byerly, K., Fenner, R., Gensemer, C., Norris, R. A., & Patel, S. (2025). Defining the chronic complexities of hEDS and HSD: A global survey of diagnostic challenges, life-long comorbidities, and unmet needs. Journal of Clinical Medicine, 14(16), 5636. https://doi.org/10.3390/jcm14165636
    • Sweerts, K. W. E., Mujagic, Z., Keszthelyi, D., & Conchillo, J. M. (2025). Analysis of antroduodenal motility in patients with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome. Alimentary Pharmacology & Therapeutics, 61(4), 702-705. https://doi.org/10.1111/apt.18471
    • Pepin, M., Schwarze, U., Superti-Furga, A., & Byers, P. H. (2000). Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. The New England Journal of Medicine, 342(10), 673–680. https://doi.org/10.1056/NEJM200003093421001
    • Stirrat, T., Wilkey, M., Kim, S., Waterman, A., & Mattar, M. (2026). Collagenous sprue across five decades (1970-2025): A systematic review. Scandinavian Journal of Gastroenterology, 61(5), 577–585. https://doi.org/10.1080/00365521.2026.2641509
    • Heyland, D., Muscedere, J., Wischmeyer, P. E., Cook, D., Jones, G., Albert, M., Elke, G., Berger, M. M., & Day, A. G. (2013). A randomized trial of glutamine and antioxidants in critically ill patients. The New England Journal of Medicine, 368(16), 1489–1497. https://doi.org/10.1056/NEJMoa1212722
    • Brueckheimer, P. J., Costa Silva, T., Rodrigues, L., Zague, V., & Isaia Filho, C. (2025). The effects of type I collagen hydrolysate supplementation on bones, muscles, and joints: A systematic review. Orthopedic Reviews, 17, 129086. https://doi.org/10.52965/001c.129086
    • Buchman, A. L., Moukarzel, A. A., Bhuta, S., Belle, M., Ament, M. E., Eckhert, C. D., Hollander, D., Gornbein, J., Kopple, J. D., & Vijayaroghavan, S. R. (1995). Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN. Journal of Parenteral and Enteral Nutrition, 19(6), 453–460. https://doi.org/10.1177/0148607195019006453
    • Rachmadi, R. A., Ariani, Y., & Alatas, F. S. (2024). Impact of nutritional supplementation on environmental enteric dysfunction (EED) in children living in rural areas: A systematic review. Arquivos de Gastroenterologia, 61, e23159. https://doi.org/10.1590/S0004-2803.24612023-159

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card The Normal B12 That Wasn't, The Angry Gut, Chapter 6

    Intrinsic Factor Antibody: Screening for Autoimmune Gastritis

    The Normal B12 That Wasn't | The Angry Gut, Chapter 6

    Intrinsic Factor Antibody: Screening for Autoimmune Gastritis

    An intrinsic factor antibody is highly specific for autoimmune gastritis but insensitive: 100% specificity and 38% sensitivity in a recent assay comparison, so a negative result settles little. Ordered together with anti-parietal cell antibody, the pair reached 90% sensitivity and 95.7% specificity.

    Autoimmune gastritis is found when someone looks for it. The serology fails in predictable directions, and the patients at risk are easy to flag before their nerves and memory pay for the delay.

    An intrinsic factor antibody is one of the few results in a B12 workup that can close a diagnosis on its own, and one of the least informative when it comes back negative. Most practices order it late, order it alone, and read a negative as reassurance. The video The Normal B12 That Wasn’t, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, walks through a patient who lost four years to exactly that sequence. For a primary care, endocrine, geriatric or pain practice the practical questions are narrower: who to screen for autoimmune gastritis, how to read the serology, and what a finding changes downstream in nerve, balance and cognitive function.

    Intrinsic factor antibody vs. parietal cell antibody: how does each test fail?

    Anti-intrinsic factor antibody carried a specificity of 100% and a sensitivity of 38% in a recent assay comparison. A United States society review puts its sensitivity under 30% in many studies and notes that it is more often positive later in the disease course. The test that proves the diagnosis turns positive after much of the damage is done. More than half of people with symptomatic B12 deficiency test negative for both antibodies.

    Anti-parietal cell antibody has the opposite profile. It is present in 85% to 90% of patients with autoimmune gastritis, but about 10% of the general population carries it, it turns positive in H. pylori gastritis and autoimmune thyroid disease, and it becomes less reliable in patients aged 50 and over, which is where the disease concentrates. Combined, the pair performed at 90% sensitivity with 95.7% specificity.

    Two workflow consequences follow. Order both, not one. And do not trend the parietal cell titer: in 282 patients followed for 18 years, neither its presence nor its value predicted histologic progression.

    Who to screen: the profile the stereotype hides

    The teaching image of an older Northern European woman misses much of the population. In a Miami biopsy series, 60 of 79 cases, 76.0%, were Hispanic, and the median age at first presentation was 51 years in Hispanic patients against 59 in White patients. Symptoms do not select either; in pooled data, gastric precursor lesions were no more common in symptomatic than in asymptomatic people. The median diagnostic delay in the autoimmune gastritis literature is 14 months. A reasonable screening trigger list, built from the same evidence:

    • Autoimmune thyroid disease. About 40% of these patients have atrophic body gastritis, and 16% carry pernicious anemia.
    • Type 1 diabetes. Risk of autoimmune gastritis runs roughly three to five times the general population.
    • Unexplained iron deficiency. In corpus-predominant atrophy it appears in as many as half of patients and often precedes the B12 fall.
    • Long-term metformin or acid suppression. In a randomized placebo-controlled trial over 4.3 years, metformin lowered serum B12 by 19%, number needed to harm 13.8. A supply of proton pump inhibitor lasting at least two years was associated with deficiency at an odds ratio of 1.65.
    • Gastric bypass. Pooled randomized trials put its B12 deficiency risk at 1.86 times that of sleeve gastrectomy.

    Case-finding pays off in the data. In the Italian network cohort, 15.3% of antibody-positive patients were identified by active search rather than symptoms, against 2.6% of antibody-negative patients. The social driver sits underneath the pharmacology: a food supply that manufactures insulin resistance and reflux, treated with drugs that draw the vitamin down. That background metaflammation is the terrain the first brain is failing in.

    What does a positive or equivocal intrinsic factor antibody change?

    I spent years repeating that gastric acid output simply declines with age. It does not; adjusted for gastritis and H. pylori, age had no independent effect. A patient with low acid and low B12 has a lesion, and the workup should treat it as one.

    Confirm functional status first. Holotranscobalamin below 25 pmol/L indicates deficiency, and 25 to 70 is indeterminate. Methylmalonic acid above 280 nmol/L suggests suboptimal status in younger patients with normal renal function, and above 750 nmol/L is accepted as definite, read in light of renal impairment, dehydration and small-bowel bacterial overgrowth. Gastrin drawn on a proton pump inhibitor is raised three to five times and reports on the drug. Pepsinogen testing is not available for routine clinical use in the United States.

    Then look at the lining. European guidance asks for at least two biopsies from the antrum or incisura and two from the corpus, in separately labeled vials. Only 9% of patients with pernicious anemia were offered gastroscopy at diagnosis in one recent study. The yield is not academic: in 1,598 Italian patients with autoimmune gastritis, presenting with low B12 or low iron predicted neuroendocrine tumors, hazard ratio 16.44, while progression from atrophic gastritis to adenocarcinoma runs about 0.1% to 0.3% per year. On route of replacement, the 2024 English guideline recommends lifelong intramuscular therapy where autoimmune gastritis is the cause; the largest oral trial enrolled only 10.8% intrinsic factor antibody-positive patients.

    Pairing the serology with nerve, balance and cognition

    Serology locates the cause. It does not tell you what the deficiency has already cost. Measura [Cardiometabolic and Autonomic Health Analysis] measures that downstream picture and returns it to the ordering physician; it does not diagnose gastritis and it does not treat.

    That pairing belongs inside existing fall-risk and cognitive screening, as outlined in cognitive assessment and fall prevention. The related case for functional B12 markers in metformin-treated patients is in metformin and B12 screening beyond the serum level, and the cognitive overlap in B vitamins in mild cognitive impairment.

    Documentation, standing orders and workflow

    This screen only works if it runs without a physician remembering it. A standing order can attach both gastric antibodies and a functional B12 marker to the trigger list above, flag unexplained low ferritin for the same bundle, and route positives to gastroenterology with the biopsy protocol spelled out. The annual wellness visit already carries cognitive and fall-risk elements that the nerve and balance measurements document, and the same findings support MIPS quality documentation. For operational detail, see making screening reproducible with standing orders. The full evidence file is in the companion deep dive for The Angry Gut, and the patient-facing explanation is atrophic gastritis and B12 absorption.

    Frequently asked questions

    Does a negative intrinsic factor antibody rule out pernicious anemia?

    No. Sensitivity was 38% in a recent assay comparison and under 30% in many studies, and the antibody tends to appear later in the disease. More than half of patients with symptomatic B12 deficiency are negative for both antibodies. A negative result with a high methylmalonic acid still warrants a look at the gastric lining. See guidance on interpreting the report.

    Should anti-parietal cell antibody titers be repeated to monitor progression?

    The evidence does not support it. In a prospective cohort of 282 patients followed for 18 years, neither the presence of anti-parietal cell antibody nor its measured value predicted histologic progression. Follow-up is better spent on functional B12 status, iron, and nerve, balance and cognitive measures that reflect what the patient is losing. Read about chronic care and between-visit monitoring.

    Which patients should be screened for autoimmune gastritis in primary care?

    Reasonable triggers include autoimmune thyroid disease, type 1 diabetes, unexplained iron deficiency, long-term metformin or acid suppression, and gastric bypass. Do not restrict screening by ethnicity or sex; in a Miami series most cases were Hispanic, with a median presentation age of 51. Symptoms are a poor filter, since precursor lesions were equally common with and without them. Review the selection criteria.

    Can gastrin be interpreted in a patient taking a proton pump inhibitor?

    Not reliably. A proton pump inhibitor raises plasma gastrin three to five times depending on duration of use, so a gastrin drawn on therapy reflects the drug rather than the stomach. Whether and how to pause acid suppression before testing is a clinical decision for the treating physician, weighed against the indication. See more physician questions.

    Where does Measura fit in a B12 malabsorption workup?

    After the cause is being pursued, not instead of it. Serology, functional markers and endoscopy establish the gastric diagnosis elsewhere. Measura adds sudomotor, balance, cognitive and metabolic measurements that document the downstream burden and give a baseline against which replacement can be judged, with results returned to the ordering physician. Read the clinical rationale.

    What does a positive intrinsic factor antibody mean?

    With 100% specificity in a recent assay comparison, a positive result effectively establishes autoimmune gastritis as the cause. The next steps are confirming functional B12 status with holotranscobalamin or methylmalonic acid, then examining the lining with at least two antrum or incisura biopsies and two corpus biopsies in separately labeled vials. The 2024 English guideline recommends lifelong intramuscular replacement where autoimmune gastritis is the cause.

    Should intrinsic factor and parietal cell antibodies be ordered together?

    Yes. They fail in opposite directions. Intrinsic factor antibody is specific but caught only 38% of cases. Anti-parietal cell antibody is present in 85% to 90% of patients but also in about 10% of the general population, in H. pylori gastritis and in autoimmune thyroid disease, and it grows less reliable from age 50. Ordered together, the pair reached 90% sensitivity and 95.7% specificity.

    What autoimmune disease causes a lack of intrinsic factor?

    Autoimmune gastritis, in which the immune system attacks the stomach’s parietal cells, the source of intrinsic factor. It clusters with other autoimmunity. About 40% of patients with autoimmune thyroid disease have atrophic body gastritis and 16% carry pernicious anemia, and type 1 diabetes carries roughly three to five times the general population’s risk of autoimmune gastritis.

    Build the downstream measurements into your B12 workup

    Learn how the Measura protocol adds nerve, balance, cognitive and metabolic measurement to a practice’s existing screening workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Osmola, M., Hémont, C., Romańczyk, M., Druet, A., Chapelle, N., Matysiak-Budnik, T., Lenti, M. V., & Martin, J. C. (2025). A comparative study of different assays for autoantibodies detection in patients with autoimmune gastritis. Journal of Translational Autoimmunity, 10, 100294. https://doi.org/10.1016/j.jtauto.2025.100294
    • Rustgi, S. D., Bijlani, P., & Shah, S. C. (2021). Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therapeutic Advances in Gastroenterology, 14, 17562848211038771. https://doi.org/10.1177/17562848211038771
    • Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325–1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
    • Thain, A., Hart, K., & Ahmadi, K. R. (2025). Addressing the gaps in the vitamin B12 deficiency 2024 NICE guidelines: Highlighting the need for better recognition, diagnosis, and management of pernicious anaemia. European Journal of Clinical Nutrition, 79(7), 607-610. https://doi.org/10.1038/s41430-025-01583-4
    • Poveda, J. C., Park, J. Y., Garcia-Buitrago, M. T., Singhi, A., Alruwaii, Z., Kumar, S., McDonald, O. G., & Montgomery, E. A. (2024). Autoimmune Metaplastic Atrophic Gastritis (AMAG): Regional Demographics and Their Effect on Prevalence. International Journal of Surgical Pathology, 33(3), 565–570. https://doi.org/10.1177/10668969241271311
    • Harrington, D. J., Stevenson, E., & Sobczyńska-Malefora, A. (2024). The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Annals of Clinical Biochemistry, 62(1), 22–33. https://doi.org/10.1177/00045632241292432
    • Lenti, M. V., Miceli, E., Lahner, E., Natalello, G., Massironi, S., Schiepatti, A., Zingone, F., Sciola, V., Rossi, R. E., Cannizzaro, R., De Giorgi, E. M., Gregorio, V., Fazzino, E., Gentile, A., Petrucci, C., Dilaghi, E., Pivetta, G., Vanoli, A., Luinetti, O., … Di Sabatino, A. (2024). Distinguishing Features of Autoimmune Gastritis Depending on Previous Helicobacter pylori Infection or Positivity to Anti-Parietal Cell Antibodies: Results From the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO). The American Journal of Gastroenterology, 119(12), 2408–2417. https://doi.org/10.14309/ajg.0000000000002948
    • de Jager, J., Kooy, A., Lehert, P., Wulffelé, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ, 340, c2181. https://doi.org/10.1136/bmj.c2181
    • Dinis-Ribeiro, M., Libânio, D., Uchima, H., Spaander, M. C. W., Bornschein, J., Matysiak-Budnik, T., Tziatzios, G., Santos-Antunes, J., Areia, M., Chapelle, N., Esposito, G., Fernandez-Esparrach, G., Kunovsky, L., Garrido, M., Tacheci, I., Link, A., Marcos, P., Marcos-Pinto, R., Moreira, L., … Kuipers, E. J. (2025). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy, 57(5), 504–554. https://doi.org/10.1055/a-2529-5025
    • National Institute for Health and Care Excellence (NICE) (2024). Vitamin B12 deficiency in over 16s: diagnosis and management (NICE guideline NG239).

    Related reading

  • Dr. Gurpreet Singh Padda in a white coat beside the title card reading Chapter 5, The Angry Gut, Alcohol you never drank

    MASLD in Primary Care: Screening When Liver Enzymes Look Normal

    The Alcohol You Never Drank | The Angry Gut, Chapter 5

    MASLD in Primary Care: Screening When Liver Enzymes Look Normal

    MASLD is under-read in primary care: ultrasound detects liver fat only once more than 30% of liver cells are involved, and the routine panel can read normal. GGT, read as a trend inside the reference interval, belongs in the metabolic workup of every patient who meets the definition.

    The definition now requires liver fat plus a cardiometabolic risk factor. That places the condition squarely in the metabolic visit, where the routine panel and the ultrasound both under-read it.

    MASLD, metabolic dysfunction-associated steatotic liver disease, is now defined by hepatic steatosis plus at least one of five cardiometabolic risk factors, a nomenclature adopted through a Delphi process with 236 panelists from 56 countries. The definition moves the condition into the metabolic visit. The video above, The Alcohol You Never Drank, covers Chapter 5 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, which treats the liver as downstream of the first brain: the gut delivers, the liver filters, and the routine workup reads the filter rather than the stream.

    Dr. Padda describes closing visits for years with an instruction to lose weight and counting it as management. The evidence below is why that sentence is not a plan for a patient who has already lost and regained the weight more than once.

    Why do normal liver enzymes and a clean ultrasound miss MASLD?

    There are three structural blind spots. Ultrasound detects steatosis only once more than 30% of hepatocytes are involved, and British guidance states that a raised GGT with metabolic risk factors may indicate fatty liver despite a normal scan. ALT, the enzyme most clinicians follow, came out null for cardiovascular mortality at 0.87 in a dose-response synthesis of 23 studies and 1,067,922 participants, where GGT predicted it at 1.62. And peripheral blood is sampled after first-pass hepatic clearance: in elective abdominal surgery, portal blood was endotoxin-positive in 97% of patients and systemic blood in 4 of 34.

    The same guideline is explicit about the trade-off of adding GGT to a first-line panel: abnormal results rise from roughly 15% to roughly 30%. They retained it anyway, because the trial cited against GGT had excluded patients with fatty liver or alcohol-related disease, the groups behind 90% of liver deaths. Specificity was traded for sensitivity in exactly the population a metabolic practice sees.

    What does a GGT inside the normal range mean?

    GGT behaves as a redox gauge: the ectoenzyme degrades extracellular glutathione to supply cysteine for antioxidant synthesis, and stressed cells upregulate it. Its prognostic signal starts inside the reference interval. In 9,687,066 Korean adults followed a median 8.3 years, the top tertile carried hazard ratios of 1.33 for all-cause and 1.29 for cardiovascular mortality after adjustment for alcohol, BMI and other liver enzymes, and the high tertile for women began at 21 IU/L. In 3,500 non-diabetic British men aged 60 to 79, the top quartile predicted incident diabetes at 3.68 after BMI adjustment and 2.69 after adding insulin resistance. Restricted to never-drinkers in seven pooled Japanese cohorts, the hazard per standard deviation of GGT was 1.81 for coronary death in women and 1.43 for cardiovascular death in men.

    The limits are part of the interpretation. GGT is nonspecific, with obesity its commonest cause. It added little to established cardiovascular prediction in pooled British surveys. Mendelian randomization found no causal effect on diabetes (odds ratio 0.88) or coronary disease (1.08). The clinical use follows from those limits: GGT is a trajectory marker of oxidative load in a patient with steatosis, not a target to lower for its own sake and not a substitute for a risk score.

    Gut delivery, insulin and the patient trials exclude

    The mechanistic case centers on portal delivery. In bariatric surgery patients, portal ethanol was a median 187-fold higher than fasting systemic blood and rose from no steatosis through steatosis to steatohepatitis; blocking alcohol dehydrogenase raised systemic ethanol 15-fold after a meal in fatty liver. Pediatric and murine work places part of the effect in clearance, with reduced hepatic alcohol dehydrogenase activity linked to insulin resistance. Pooled blood endotoxin was higher in simple steatosis (standardized difference 0.86) and steatohepatitis (0.81) independent of BMI. No clinical study has yet tested the causal chain, and in adolescents endotoxin markers tracked total body fat (r = 0.64) rather than histology.

    Two biological drivers, gut-derived endotoxin and ethanol on one side and insulin-resistant hepatic handling on the other, converge on the same organ. The third driver is economic: subsidized sweetener in most packaged food supplies the substrate for fermentation. The less obvious point for screening is that the liver responds to what is delivered, not only to how much is eaten. Inulin raised hepatic fat from 20.9% to 26.8% over six weeks in a small trial, while four months of resistant starch lowered intrahepatic triglyceride 9.08%, or 5.89% after adjustment for weight loss. In the largest synbiotic trial, weight loss alone moved liver fat. Both findings can hold at once, and body weight captures neither.

    Who should be tested for MASLD?

    • Adults meeting the MASLD definition, or with an incidental echogenic liver on imaging done for another reason.
    • Patients whose GGT rises across serial panels while staying inside the reference interval.
    • Normal-BMI patients with features of insulin resistance, including South Asian patients who are thin outside and fat inside.
    • Patients repeatedly counseled to lose weight with no measurement of what changed.

    Written selection criteria make that list reproducible across clinicians.

    What the measurements add, and what a finding changes

    Measura [Cardiometabolic and Autonomic Health Analysis] does not image the liver; confirming steatosis stays with radiology. What it measures is the terrain that decides risk:

    A finding changes management when it relocates the patient. Steatosis with a rising GGT and abnormal vascular measures belongs in active cardiovascular prevention rather than a weight handout. Adverse body composition at normal BMI reframes counseling around insulin and dietary delivery, with lifestyle work prescribed as treatment and its physiological rationale documented. Measurement repeated on a schedule shows whether the terrain moved, which no single panel can.

    Workflow and documentation

    Build eligibility into standing orders so testing does not depend on who remembers. Findings recorded at the annual wellness visit, beside the cognitive and fall screening already structured there (see cognitive assessment and fall prevention), support the measures discussed in HEDIS and value-based care. The patient version, written for someone holding an echogenic ultrasound report, is what an echogenic liver means. The barrier upstream of the portal vein is covered in metabolic endotoxemia screening, and every cohort cited here is set out with its limits in the Chapter 5 companion. The same unrecognized liver disease can surface as confusion in older patients, which is why screening for cirrhosis in dementia belongs in the cognitive workup.

    Frequently asked questions

    Does a normal ultrasound exclude MASLD?

    No. Ultrasound becomes sensitive to steatosis only once more than 30% of hepatocytes carry fat, so milder disease scans clean. British guidance notes that a raised GGT in a patient with metabolic risk factors may still reflect fatty liver behind a normal scan. The measurement rationale is expanded in clinical rationale.

    How should an in-range GGT be interpreted?

    As a position on a risk gradient rather than a pass. Pooled cohorts show cardiovascular mortality rising within the reference interval, at 1.10 per 10 U/L across 527,589 participants. Because GGT is nonspecific and not causal by Mendelian randomization, serial values read in context carry more information than any single reading. Reading trends is covered in interpreting the report.

    Should suspected gut-derived ethanol prompt testing for auto-brewery syndrome?

    Not routinely. The portal ethanol finding describes concentrations cleared on first pass, not intoxication. Auto-brewery syndrome is rare, its literature covers 165 patients across case reports and series, and a single blood alcohol reading does not establish it. The practical target is the metabolic terrain that governs delivery and clearance. Common physician questions are collected in physician questions.

    Does Measura image the liver?

    No. Ultrasound and other liver imaging are performed elsewhere. Measura measures the laboratory, body composition and vascular picture around steatosis and returns findings to the ordering physician, who retains diagnosis and treatment. How the protocol is introduced into a practice is described in onboarding the Measura protocol.

    How often should these measures be repeated?

    The evidence summarized here sets no fixed interval. The clinical logic is trajectory: GGT, insulin measures, body composition and vascular function repeated at planned visits show whether changes in dietary delivery and insulin resistance are moving the terrain. Documenting the interval in advance keeps follow-up consistent. Between-visit structures are discussed in chronic care and between-visit monitoring.

    What is the difference between NAFLD and MASLD?

    The difference is the definition. MASLD, metabolic dysfunction-associated steatotic liver disease, is the name set by the new fatty liver disease nomenclature, adopted through a Delphi process with 236 panelists from 56 countries. It requires liver fat plus at least one of five cardiometabolic risk factors. That ties the diagnosis to metabolism and places it in the metabolic visit, where the routine panel and the ultrasound both under-read it.

    Can you have fatty liver with normal liver enzymes?

    Yes. The routine panel can read normal while fat sits in the liver. ALT, the enzyme most clinicians follow, did not predict cardiovascular death in a synthesis of 23 studies, while GGT did. Blood drawn from the arm is also sampled after the liver has already filtered what the gut delivered. GGT, read as a trend inside the reference interval, belongs in the workup of anyone who meets the MASLD definition.

    Does fatty liver go away?

    Liver fat moves, and what reaches the liver matters as much as how much is eaten. In the trials cited here, four months of resistant starch lowered liver triglyceride by 9.08%, or 5.89% after adjusting for weight loss, while inulin raised liver fat from 20.9% to 26.8% over six weeks. Weight loss alone also moved liver fat. Repeating the measurements on a schedule shows whether the terrain is changing.

    Measure the terrain around the liver

    Learn how the Measura protocol adds serial laboratory, body composition and vascular measurement to the metabolic visits your practice already runs.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Castro Narro, G. E., Chowdhury, A., Cortez-Pinto, H., … Newsome, P. N. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966-1986. https://doi.org/10.1097/HEP.0000000000000520
    • Newsome, P. N., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., Hall, R., Harrower, U., Hudson, M., Langford, A., Mackie, A., Mitchell-Thain, R., Sennett, K., Sheron, N. C., Verne, J., Walmsley, M., & Yeoman, A. (2018). Guidelines on the management of abnormal liver blood tests. Gut, 67(1), 6-19. https://doi.org/10.1136/gutjnl-2017-314924
    • Rahmani, J., Miri, A., Namjoo, I., Zamaninour, N., Maljaei, M. B., Zhou, J. B., Shokouhi Nasab Kermani, R., Kord Varkaneh, H., Fatahi, S., & Zhang, Y. (2019). Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. European Journal of Gastroenterology & Hepatology, 31(5), 555–562. https://doi.org/10.1097/MEG.0000000000001353
    • Jacob, A. I., Goldberg, P. K., Bloom, N., Degenshein, G. A., & Kozinn, P. J. (1977). Endotoxin and bacteria in portal blood. Gastroenterology, 72(6), 1268–1270. https://pubmed.ncbi.nlm.nih.gov/858472/
    • Cho, E. J., Jeong, S.-M., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K.-N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2023). Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study. Scientific Reports, 13(1), 1751. https://doi.org/10.1038/s41598-022-25970-0
    • Wannamethee, S. G., Shaper, A. G., Lennon, L., & Whincup, P. H. (2005). Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care, 28(12), 2913-2918. https://doi.org/10.2337/diacare.28.12.2913
    • Li, Y., Iso, H., Cui, R., Murakami, Y., Yatsuya, H., Miura, K., Nagasawa, S.-Y., Ueshima, H., & Okamura, T. (2016). Serum gamma-glutamyltransferase and mortality due to cardiovascular disease in Japanese men and women. Journal of Atherosclerosis and Thrombosis, 23(7), 792-799. https://doi.org/10.5551/jat.32698
    • Liu, J., Au Yeung, S. L., Lin, S. L., Leung, G. M., & Schooling, C. M. (2016). Liver enzymes and risk of ischemic heart disease and type 2 diabetes mellitus: A Mendelian randomization study. Scientific Reports, 6, 38813. https://doi.org/10.1038/srep38813
    • Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dallinga-Thie, G. M., Havik, S. R., Ackermans, M. T., … Nieuwdorp, M. (2022). Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nature Medicine, 28(10), 2100–2106. https://doi.org/10.1038/s41591-022-02016-6
    • Ni, Y., Qian, L., Siliceo, S. L., Long, X., Nychas, E., Liu, Y., Ismaiah, M. J., Leung, H., Zhang, L., Gao, Q., Wu, Q., Zhang, Y., Jia, X., Liu, S., Yuan, R., Zhou, L., Wang, X., Li, Q., Zhao, Y., … Jia, W. (2023). Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metabolism, 35(9), 1530-1547.e8. https://doi.org/10.1016/j.cmet.2023.08.002

    Related reading

  • Dr. Gurpreet Singh Padda in a white coat beside the title card reading Chapter 4, The Angry Gut, The Permeable Fortress

    Metabolic Endotoxemia: What to Measure When Zonulin Cannot

    The Leaky Gut Test You Paid For Cannot See the Wall | The Angry Gut, Chapter 4

    Metabolic Endotoxemia: What to Measure When Zonulin Cannot

    Metabolic endotoxemia is bacterial endotoxin leaking from the gut into the blood at levels that disturb metabolism. Screening it in primary care means measuring the response rather than the exposure: insulin resistance, adipose-driven inflammation and vascular risk.

    Barrier failure is measurable and, in one cohort, preceded disease by years. The serum marker patients bring in does not measure it, and the downstream metabolic injury is where screening earns its place.

    Metabolic endotoxemia, the passage of bacterial endotoxin from the gut into the circulation at levels that disturb metabolism, is usually filed as a gastroenterology question. Its measurable consequences land in primary care: insulin resistance, adipose inflammation and vascular risk. The accompanying chapter video covers Chapter 4 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. For a screening program the book’s case reduces to three propositions: barrier failure is real and measurable, the serum marker patients arrive with does not measure it, and the downstream metabolic injury is where measurement changes management.

    The barrier in question is the outer surface of what the book calls the first brain, with the skull holding the second brain, and metaflammation begins where that barrier fails. Dr. Padda was trained to dismiss a zonulin printout and abandoned the reflex; neither the dismissal nor the printout survives the evidence.

    The zonulin assay has failed validation twice

    Zonulin was characterized as pre-haptoglobin-2. Scheffler and colleagues measured serum zonulin with the most widely used commercial ELISA in 376 people genotyped for haptoglobin. Readings did not follow genotype, the kit returned signal in individuals who cannot synthesize the target, and it did not detect the purified protein; the leading candidate for what it binds is properdin. Ajamian and colleagues tested two further commercial kits and identified the bound material by mass spectrometry as haptoglobin and a complement protein.

    Power and colleagues then ran the comparison that matters clinically, serum zonulin against the lactulose-to-mannitol test in first-degree relatives of patients with Crohn’s disease: r2 = 0.004, p < 0.71. In a head-to-head evaluation of six candidate markers in 78 people, only plasma LBP tracked the sugar test in every cohort; plasma zonulin and plasma I-FABP did not.

    The originators now describe zonulin as a family of proteins that includes properdin, a position built on a cultured cell monolayer. Whatever the kits detect does rise with obesity, diabetes, and glucose and lipid markers. That makes the result a vague metabolic signal rather than a barrier measurement, and it should not anchor a diagnosis or an elimination diet in the chart.

    How is intestinal permeability measured?

    Permeability is measured functionally, with oral sugar probes and timed urine collection. Validation in 60 healthy adults on controlled diets established reference recoveries and three practical constraints. Unlabeled mannitol was present in baseline urine in every participant, so the labeled isotope is required. Between-person variation was large, with a median coefficient of variation of 76.5%. And the conventional lactulose-to-mannitol ratio is a weak statistic: in inflammatory bowel disease, labeled mannitol (P = .003) and lactulose (P = .006) each separated patients from volunteers while the ratio did not (P = .237).

    None of this is offered by Measura [Cardiometabolic and Autonomic Health Analysis]; it is a referral-level investigation ordered when a gastrointestinal question warrants it.

    Done properly, barrier measurement has prognostic weight in at least one cohort. In 1,420 healthy first-degree relatives of patients with Crohn’s disease followed a median 7.8 years, abnormal baseline permeability predicted Crohn’s disease at a hazard ratio of 3.03 (95% CI, 1.64-5.63), and at 1.62 when restricted to tests done more than three years before diagnosis. The counterpoint belongs beside it: relatives from multiplex families carried a 3.65-fold risk without more permeable barriers, and a graded review of eight studies in obesity and metabolic syndrome found very low to low certainty and no clear relationship. The practice position is that the barrier is one road into metabolic disease, and the evidence tier for the metabolic link is mechanism.

    How does endotoxin cause insulin resistance?

    The human endotoxin challenge is the cleanest mechanistic evidence. In twenty healthy volunteers given 3 ng/kg intravenously, peripheral insulin sensitivity fell 35% at 24 hours while the acute insulin response was unchanged (711 to 744, P = 0.7), and HOMA-IR rose from 1.56 to 2.17. It was a pharmacological bolus that produced fever, not chronic low-grade exposure, and the investigators say so.

    The dietary version is subtler and closer to clinic. After a 910-calorie high-fat, high-carbohydrate meal, plasma endotoxin rose 47%, mononuclear-cell TLR4 and SOCS-3 expression rose, and NF-kappaB binding increased 72%, yet plasma CRP and TNF-alpha did not change. A routine inflammatory marker can stay normal while the signaling that produces insulin resistance is active.

    Across ten years in 7,169 adults, the top quartile of endotoxin activity carried 52% higher risk of incident diabetes than the bottom; per unit the hazard ratio was 1.004, and activity rose linearly with the number of metabolic syndrome components. In women in The Gambia measured by mass spectrometry, endotoxin was 57% higher with obesity plus diabetes and no different between women with and without obesity, while adipose macrophage markers rose in a clean gradient across the three groups.

    The screening insight is that exposure and response diverge. Eighteen healthy men overfed by 760 kcal a day for eight weeks raised postprandial endotoxemia 160%, yet only half of the postprandial arm mounted an inflammatory response. Everyone was exposed; the terrain decided who was injured. Screening the exposure tells you little. Screening the response, insulin resistance and adipose-driven inflammation, tells you who needs management.

    Vascular and cognitive signals worth pairing

    Endotoxin’s best-documented destination is the arterial wall. In a Finnish cohort of 2,452 adults followed ten years, high endotoxin activity predicted coronary events at a hazard ratio of 1.88; in the Bruneck population, endotoxin above the 90th percentile carried an odds ratio of 2.9 for developing carotid atherosclerosis, concentrated in smokers. Arterial stiffness and endothelial function measure the vessel the mechanism points at, whichever explanation wins.

    The second brain is exposed too. In 51 women given high-saturated-fat and high-oleic meals in crossover, higher baseline LBP predicted less consistent post-meal attention (P = 0.04); endotoxin itself was not measured and two-thirds were breast cancer survivors. That is a thin but specific reason to record a cognitive assessment baseline in the same patients, alongside the work described in cognitive assessment and fall prevention.

    Who should be tested for metabolic endotoxemia, and what does a finding change?

    • Patients presenting with a commercial zonulin result or a self-directed elimination diet. The result is not actionable; the metabolic question behind it is.
    • Long-term daily NSAID users, heavy drinkers and patients with periodontal disease. Each carries a measured barrier or endotoxin exposure, and the indication belongs in the problem list.
    • Normal-weight patients with features of insulin resistance. The Gambian gradient followed diabetes, not body size, which is where bioimpedance body composition earns its place over BMI.

    Food environments built around high-fat, high-sugar meals, over-the-counter anti-inflammatories, and short visits that reward refills over workups all load the same barrier. A finding changes management when it moves a patient from reassurance to a metabolic plan: laboratory panels quantifying insulin resistance, body composition defining the fat and muscle compartments, and lifestyle work prescribed as treatment with its physiological reason documented. Findings that raise a true gastrointestinal question go to gastroenterology for validated permeability testing. Written selection criteria keep that consistent across clinicians.

    Standing orders and documentation

    Criteria like these belong in standing orders so they run the same way for every eligible patient rather than by memory. Insulin resistance, body composition and vascular findings documented at the annual wellness visit support the measures described in MIPS and quality reporting, and structured results reach the chart through getting results into the record. The patient-facing version, written for someone holding a zonulin printout, is how to test for leaky gut. The liver, first to receive what crosses the barrier, is the subject of MASLD in primary care, and every study cited here is set out with its limits in the Chapter 4 companion.

    Frequently asked questions

    Should serum zonulin be used to screen for intestinal permeability?

    No. Commercial zonulin assays failed validation in two independent laboratories, did not follow haptoglobin genotype, and showed no correlation with a lactulose-to-mannitol test in the same subjects. Whatever they detect tracks obesity and glycemia, so that metabolic signal is better measured directly. The screening logic for cardiometabolic measurement is laid out in clinical rationale.

    Is intestinal permeability testing part of the Measura protocol?

    No. Timed urine sugar-probe testing with labeled mannitol is a gastroenterology investigation performed elsewhere. Measura measures the downstream terrain: laboratory markers of insulin resistance and inflammation, body composition, vascular function and cognition, with findings returned to the ordering physician. How those measures fit different specialties is described in specialty applications.

    What does metabolic endotoxemia change in management?

    It reframes insulin resistance in a patient without obesity as a signaling problem worth measuring rather than a weight problem to be waved off. A documented decline in insulin sensitivity, an adverse fat-to-muscle profile or abnormal vascular function moves the patient into an active metabolic plan with repeat measurement. Reading those results in context is covered in interpreting the report.

    How do these findings fit the annual wellness visit?

    The wellness visit already structures risk assessment, cognitive screening and a written prevention plan. Metabolic, body composition and vascular findings slot into that plan as measured risk factors with a repeat interval, which makes change over time documentable rather than anecdotal. Practical placement within the visit is described in annual wellness visit integration.

    How is metabolic endotoxemia treated?

    By measuring and managing the response rather than the exposure. A finding moves the patient from reassurance to a metabolic plan: laboratory panels that quantify insulin resistance, body composition that defines the fat and muscle compartments, and lifestyle work prescribed as treatment with its physiological reason documented, followed by repeat measurement. Findings that raise a true gastrointestinal question go to gastroenterology for validated permeability testing.

    Put the downstream measures in the workflow

    Learn how the Measura protocol adds metabolic, body composition and vascular measurement to the visits your practice already runs.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Scheffler, L., Crane, A., Heyne, H., Tonjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
    • Power, N., Turpin, W., Espin-Garcia, O., Smith, M. I., CCC GEM Project Research Consortium, & Croitoru, K. (2021). Serum zonulin measured by commercial kit fails to correlate with physiologic measures of altered gut permeability in first degree relatives of Crohn’s disease patients. Frontiers in Physiology, 12, 645303. https://doi.org/10.3389/fphys.2021.645303
    • Seethaler, B., Basrai, M., Neyrinck, A. M., Nazare, J. A., Walter, J., Delzenne, N. M., & Bischoff, S. C. (2021). Biomarkers for assessment of intestinal permeability in clinical practice. American Journal of Physiology. Gastrointestinal and Liver Physiology, 321(1), G11–G17. https://doi.org/10.1152/ajpgi.00113.2021
    • Khoshbin, K., Khanna, L., Maselli, D., Atieh, J., Breen-Lyles, M., Arndt, K., Rhoten, D., Dyer, R. B., Singh, R. J., Nayar, S., Bjerkness, S., Harmsen, W. S., Busciglio, I., & Camilleri, M. (2021). Development and validation of test for “leaky gut” small intestinal and colonic permeability using sugars in healthy adults. Gastroenterology, 161(2), 463–475.e13. https://doi.org/10.1053/j.gastro.2021.04.020
    • Turpin, W., Lee, S.-H., Raygoza Garay, J. A., Madsen, K. L., Meddings, J. B., Bedrani, L., Power, N., Espin-Garcia, O., Xu, W., Smith, M. I., Griffiths, A. M., Moayyedi, P., Turner, D., Seidman, E. G., Steinhart, A. H., Marshall, J. K., Jacobson, K., Mack, D., Huynh, H., … Croitoru, K. (2020). Increased intestinal permeability is associated with later development of Crohn’s disease. Gastroenterology, 159(6), 2092–2100.e5. https://doi.org/10.1053/j.gastro.2020.08.005
    • Bona, M. D., Torres, C. H. de M., Lima, S. C. V. C., Morais, A. H. de A., Lima, A. Â. M., & Maciel, B. L. L. (2022). Intestinal barrier permeability in obese individuals with or without metabolic syndrome: a systematic review. Nutrients, 14(17), 3649. https://doi.org/10.3390/nu14173649
    • Mehta, N. N., McGillicuddy, F. C., Anderson, P. D., Hinkle, C. C., Shah, R., Pruscino, L., Tabita-Martinez, J., Sellers, K. F., Rickels, M. R., & Reilly, M. P. (2010). Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes, 59(1), 172–181. https://doi.org/10.2337/db09-0367
    • Ghanim, H., Abuaysheh, S., Sia, C. L., Korzeniewski, K., Chaudhuri, A., Fernandez-Real, J. M., & Dandona, P. (2009). Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: Implications for insulin resistance. Diabetes Care, 32(12), 2281–2287. https://doi.org/10.2337/dc09-0979
    • Laugerette, F., Alligier, M., Bastard, J.-P., Drai, J., Chanséaume, E., Lambert-Porcheron, S., Laville, M., Morio, B., Vidal, H., & Michalski, M.-C. (2014). Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Molecular Nutrition & Food Research, 58(7), 1513–1518. https://doi.org/10.1002/mnfr.201400044
    • Madison, A. A., Belury, M. A., Andridge, R., Shrout, M. R., Renna, M. E., Malarkey, W. B., Bailey, M. T., & Kiecolt-Glaser, J. K. (2020). Afternoon distraction: A high-saturated-fat meal and endotoxemia impact postmeal attention in a randomized crossover trial. The American Journal of Clinical Nutrition, 111(6), 1150–1158. https://doi.org/10.1093/ajcn/nqaa085

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading Two Doctors, One Nerve, The Angry Gut, Chapter 3

    The LF/HF Ratio Is Not Vagal Tone: Autonomic Testing in Gut Patients

    Two Doctors, One Nerve | The Angry Gut, Chapter 3

    The LF/HF Ratio Is Not Vagal Tone: Autonomic Testing in Gut Patients

    The LF/HF ratio is not a measure of vagal tone: it climbs as autonomic input to the heart is removed. RMSSD and high-frequency power are the heart rate variability indices that carry vagal information, measured serially against the patient’s own baseline under matched conditions.

    Heart rate variability is a cardiac proxy with a consistent signal in functional and inflammatory gut disease. Its value depends on reporting the right index, under matched conditions, against the same patient.

    The LF/HF ratio is still printed on consumer devices and in some reports as sympathovagal balance. In a physiology review of that ratio, it rose from 1.1 to 8.4 when most autonomic input to the heart was removed. An index that climbs as the nerve is taken away cannot be read as vagal tone, and it should not anchor a clinical decision in a patient with functional gut symptoms.

    Chapter 3 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, shown on camera as Two Doctors, One Nerve, argues that bowel symptoms and anxiety in the same patient are one autonomic and inflammatory problem split across two specialties. Measura [Cardiometabolic and Autonomic Health Analysis] measures the cardiac side of that problem and reports to the ordering physician. The questions for a practice are which indices carry vagal information, how large the gut signal really is, and what a finding should change.

    Does the LF/HF ratio measure vagal tone?

    The Task Force standards set high frequency at 0.15 to 0.40 Hz and made five minutes the short-term recording standard. Two constraints follow. High-frequency power indexes vagal tone only while respiration stays inside that band, roughly nine to twenty-four breaths per minute, which is why RMSSD, less affected by breathing, is the preferred vagal index for most purposes. Recording lengths are also not interchangeable; 24-hour, five-minute and ultra-short values are distinct measurements.

    The ratio’s problems are anatomical. Parasympathetic blockade removes at least half of low-frequency power, the sympathetic share of that band is at best a quarter, sympathetic activation may shift high-frequency power by up to ten percent, and prevailing heart rate biases the ratio with no change in nerve activity. Denervated transplanted hearts still show two to eight percent of normal respiratory variation. Report RMSSD and high-frequency power, and leave LF/HF uninterpreted.

    Between-subject comparison is the weak use of these indices. Respiratory sinus arrhythmia often correlates strongly with vagal control inside one person and only modestly across people, so the defensible clinical use is serial measurement against the patient’s own baseline under matched conditions. A Measura heart rate variability recording can be repeated for that purpose, and cardiac autonomic reflex tests add standardized provocations to the resting picture.

    Is heart rate variability lower in gut disorders?

    Pooled across inflammatory bowel disease, RMSSD sat at a standardized difference of -0.71 against controls; removing one influential study shrank the ulcerative colitis estimate to -0.41. In irritable bowel syndrome, a high-frequency deficit appeared in short recordings (-0.35) and was essentially absent in long ones (-0.06). Only 2 of 28 studies in that review confirmed a blinded reader, and its authors judged heart rate variability not yet suitable for monitoring symptoms in either condition.

    Within single cohorts the signal is clearer. Among 253 participants with 24-hour recordings, the vagal index ran 39.99 ms in controls and 16.87 ms in functional dyspepsia, and the normal postprandial organization of gastric slow waves was blunted alongside it. In adjusted models, sleep quality outperformed anxiety and depression scores as a predictor of vagal tone, with a coefficient of -1.726 and an adjusted R-squared of 0.583. In Crohn’s disease, vagal tone correlated inversely with circulating TNF (r = -0.48); in irritable bowel syndrome, with plasma epinephrine (r = -0.39); in no group did it follow affect scores.

    Stated at its tier, this is a soft instrument with a consistent direction, sensitive to study design, and a proxy for cardiac rather than abdominal vagal tone. It does not measure vagal traffic from the gut. The practice’s position is that it is worth measuring anyway, because the direction holds across cohorts and pooled reviews, and because trial exclusions remove the patients who carry the most risk.

    Which gut patients should have autonomic testing?

    Reasonable candidates include adults with functional dyspepsia or irritable bowel syndrome whose anxiety is managed on a separate track, patients with inflammatory bowel disease and persistent symptoms, and the cardiometabolic patient the pooled gut analysis excluded: cardiovascular disease, diabetes, kidney failure, alcoholism, or treatment with a beta-blocker or calcium channel blocker. Those groups can be written into selection criteria, with the medication list recorded as a confounder.

    A low, reproducible vagal index changes management in three ways. It supports handling the bowel and the anxiety as one case, with gastroenterology and behavioral plans coordinated instead of run in parallel. It moves sleep assessment up the list, since sleep was the strongest predictor in the dyspepsia cohort. And it prompts a look at the metaflammation terrain feeding the ascending signal, through laboratory panels and the broader autonomic nervous system testing battery. A normal value does not exclude a gut-driven problem, and a low one is not a diagnosis.

    Can a change in heart rate variability prove an anti-inflammatory vagal effect?

    Dr. Padda learned the vagus-to-spleen inflammatory reflex as settled physiology and taught it that way. The route has not held. In rats, vagotomy left endotoxin-induced plasma TNF unchanged while section of the greater splanchnic nerve raised it about fivefold, and anatomical tracing in mice found no significant vagal motor supply to the spleen. Across 15 stimulation studies, pooled effects on TNF, interleukin-6 and interleukin-1 beta were not significant, and a higher risk of bias predicted a larger reported effect.

    Two reporting consequences follow. A change in heart rate variability after an intervention is not evidence of an anti-inflammatory vagal effect. And interventions named for vagal tone may leave it untouched: across 13 randomized trials and 965 participants with cardiovascular disease, heart rate variability biofeedback reduced diastolic pressure by 3.23 mmHg without shifting high-frequency power. Stimulation devices and biofeedback programs are treatments, not measurements, and are not part of the Measura protocol.

    How should heart rate variability be recorded for serial testing?

    Reproducibility is the entire value of a serial autonomic measure, so the protocol has to fix what the physiology responds to: the same device and analysis method, the same time of day and posture, spontaneous breathing with no breathing exercise beforehand, a documented recording length, and a current medication list flagging agents that alter heart rate. Paced breathing inflates almost every index, and two spectral methods applied to one recording return different values. Standing orders make those conditions the default, staffing and workflow covers who runs the recording, and results enter the record as dated, comparable values. For patients followed over time, between-visit monitoring keeps the trend in view. The anatomy behind the proxy is covered in the opening physician post in this series.

    The complete evidence file, including the pooled results that shrink the effect, is in the Deep Dive companion. The preceding installment covers the medication load feeding the first brain’s signal to the second brain, in deprescribing starts with a baseline.

    Frequently asked questions

    What does a high LF/HF ratio mean?

    Less than most apps imply. The ratio is printed as sympathovagal balance, yet in a physiology review it rose from 1.1 to 8.4 when most autonomic input to the heart was removed. Prevailing heart rate also shifts it with no change in nerve activity. A high ratio is not evidence of a stressed nervous system or of low vagal tone, and it should not anchor a clinical decision.

    What do LF and HF mean in heart rate variability?

    They are frequency bands of heart rate variability. High frequency, 0.15 to 0.40 Hz under the Task Force standards, follows breathing and indexes vagal tone while respiration stays between roughly nine and twenty-four breaths per minute. Low frequency is not a sympathetic measure: parasympathetic blockade removes at least half of its power, and the sympathetic share is at best a quarter.

    Should I worry if my heart rate variability is low?

    A single low value is a reason for a closer look, not a diagnosis. A low vagal index that reproduces under matched conditions supports treating bowel symptoms and anxiety as one case, moves sleep assessment up the list, and prompts a look at the metabolic and inflammatory terrain. A normal value does not exclude a gut-driven problem, so the trend against your own baseline matters most.

    Should the LF/HF ratio appear in a clinical autonomic report?

    Not as a measure of sympathovagal balance. The ratio rose from 1.1 to 8.4 when most autonomic input was removed, low-frequency power is at least half parasympathetic, and heart rate alone shifts the ratio. If a system prints it, label it a spectral ratio and base interpretation on RMSSD and high-frequency power. Interpreting the report.

    Is RMSSD or high-frequency power preferable in gut patients?

    RMSSD, for most uses. High-frequency power indexes vagal tone only when breathing falls between roughly nine and twenty-four breaths per minute, and slower breathers push vagal activity out of the band. RMSSD is less sensitive to respiration. Whichever is reported, keep the recording length and analysis method constant between visits. What makes a good vascular and autonomic tester.

    Does a low vagal index confirm gut-driven inflammation?

    No. It is a cardiac proxy associated with inflammatory markers and with gut disorders in group data, not a measurement of abdominal vagal traffic or of mucosal inflammation. Treat it as a terrain marker that justifies a closer look at inflammation, sleep and sympathetic load, alongside the gastrointestinal workup ordered elsewhere. Clinical rationale.

    Which factors confound heart rate variability in these patients?

    Breathing rate, posture, momentary physical activity, prevailing heart rate, recording length and the analysis method all shift the values, and beta-adrenergic tone alters respiratory sinus arrhythmia. Beta-blockers and calcium channel blockers were exclusion criteria in the pooled gut analysis, so document them and compare each patient only with their own prior recordings. Physician questions.

    How should serial results be documented?

    Record the index reported, recording length, time, posture, device, analysis method, breathing conditions and current medications with every value. That makes a trend defensible and lets a colleague reproduce the measurement. Document the management decision each result informed, including a decision that nothing changed. Getting diagnostic results into the chart.

    Make the vagal index reproducible

    Learn how the Measura protocol standardizes heart rate variability and autonomic reflex testing for serial use in a practice’s gut and cardiometabolic patients.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (1996). Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation, 93(5), 1043-65. https://pubmed.ncbi.nlm.nih.gov/8598068/
    • Laborde, S., Mosley, E., & Thayer, J. F. (2017). Heart rate variability and cardiac vagal tone in psychophysiological research – recommendations for experiment planning, data analysis, and data reporting. Frontiers in Psychology, 8, 213. https://doi.org/10.3389/fpsyg.2017.00213
    • Billman, G. E. (2013). The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. Frontiers in Physiology, 4, 26. https://doi.org/10.3389/fphys.2013.00026
    • Grossman, P., & Taylor, E. W. (2007). Toward understanding respiratory sinus arrhythmia: relations to cardiac vagal tone, evolution and biobehavioral functions. Biological Psychology, 74(2), 263-85. https://doi.org/10.1016/j.biopsycho.2005.11.014
    • Kim, K.-N., Yao, Y., & Ju, S.-Y. (2020). Heart rate variability and inflammatory bowel disease in humans: a systematic review and meta-analysis. Medicine, 99(48), e23430. https://doi.org/10.1097/MD.0000000000023430
    • Sadowski, A., Dunlap, C., Lacombe, A., & Hanes, D. (2021). Alterations in heart rate variability associated with irritable bowel syndrome or inflammatory bowel disease: a systematic review and meta-analysis. Clinical and Translational Gastroenterology, 12(1), e00275. https://doi.org/10.14309/ctg.0000000000000275
    • Du, L., Yang, J., Jiang, L., Zeng, G., Shu, Y., & Bi, B. (2026). Postprandial attenuation of gastric slow waves in anxiety-depression, with and without functional dyspepsia: associations with heart rate variability and sleep quality. Frontiers in Medicine, 13, 1890716. https://doi.org/10.3389/fmed.2026.1890716
    • Pellissier, S., Dantzer, C., Mondillon, L., Trocme, C., Gauchez, A.-S., Ducros, V., Mathieu, N., Toussaint, B., Fournier, A., Canini, F., & Bonaz, B. (2014). Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn’s disease and irritable bowel syndrome. PLoS One, 9(9), e105328. https://doi.org/10.1371/journal.pone.0105328
    • de Melo, P. S., Gianlorenco, A. C., Marduy, A., Kim, C. K., Choi, H., Song, J.-J., & Fregni, F. (2024). A mechanistic analysis of the neural modulation of the inflammatory system through vagus nerve stimulation: A systematic review and meta-analysis. Neuromodulation: Journal of the International Neuromodulation Society, 28(1), 43-53. https://doi.org/10.1016/j.neurom.2024.03.002
    • Kaneko, K., Aikawa, G., Sakuramoto, H., Ota, Y., Oyama, Y., Tomooka, M., Naya, K., Fukunaga, T., Sugishima, K., & Yamada, T. (2026). Effects of heart rate variability biofeedback on cardiac autonomic function in patients with cardiovascular disease: a systematic review and meta-analysis. Applied Psychophysiology and Biofeedback. Advance online publication. https://doi.org/10.1007/s10484-025-09765-3

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading Two-Thirds of Your Pill Is Not the Drug, The Angry Gut, Chapter 2

    Deprescribing Starts With a Baseline, Not a Drug List

    Two-Thirds of Your Pill Is Not the Drug | The Angry Gut, Chapter 2

    Deprescribing Starts With a Baseline, Not a Drug List

    Deprescribing should start from a current baseline measurement, not the drug list alone, because the list holds no record of whether the physiology each drug was started for has moved. Measura supplies those measurements; the ordering physician owns every deprescribing decision.

    A medication review checks what a patient takes. It rarely checks whether the reasons each drug was started are still true, and that second question needs a measurement.

    Deprescribing is usually organized around the drug list: interactions, duplications, criteria for older adults. The list is the wrong unit of analysis for two reasons. It omits the formulation chemistry that makes up most of each tablet’s mass, and it holds no record of whether the physiology each drug was started for has moved. A multi-drug patient reviewed without a current measurement is being deprescribed on memory.

    Chapter 2 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, shown on camera as Two-Thirds of Your Pill Is Not the Drug, builds its argument around a single sixty-eight-year-old on nine prescriptions. Measura [Cardiometabolic and Autonomic Health Analysis] does not audit medications or advise on them. It supplies measurements to the ordering physician, who owns every decision. The sections below cover where those measurements fit a deprescribing workflow and where they do not.

    Who should be considered for deprescribing?

    The population is large. In one analysis of US prescribing, 39.0% of adults over 65 took at least five prescription medications daily, and a patient on 10 prescriptions ingests an average of 2.8 g of inactive ingredients per day. The index case will be familiar to primary care, pain and geriatric clinicians: a statin, an antihypertensive, metformin, a proton pump inhibitor renewed for eleven years, a daily NSAID, low-dose aspirin, an antidepressant, a laxative and a multivitamin, with bloating, alternating bowel habit and fatigue attributed to age.

    Three features should flag the chart. A daily agent whose indication has not been revisited in years. A gastrointestinal symptom managed with another prescription. A symptom attributed to age with no measurement behind the attribution. In the index bag, the laxative was treating what the other eight bottles produced. Those features can be written into selection criteria instead of being left to recall.

    What is in a pill besides the drug?

    By mass, the most prescribed US oral medications are about 75% inactive ingredient, and 92.8% of oral solids contain at least one potential allergen. Only 28% of active ingredients have a formulation that avoids all of them. The substitution space is still wide: the 18 most prescribed oral drugs average 82.5 alternative formulations per active ingredient, and levothyroxine exists in 140 formulations made by 43 manufacturers. For many patients the actionable move is reformulation rather than discontinuation.

    The exposure that matters for the gut is luminal, not systemic. Excipients that never reach meaningful plasma concentrations can sit at hundreds of micromolar to millimolar inside the gastrointestinal tract. Titanium dioxide is the worked example. In rats fed food-grade particles at dietary levels for 100 days, colonic TNF-α rose 26% and IL-8 rose 45%, with no change in paracellular permeability: immune disturbance supported, barrier failure in a healthy animal not shown. Europe removed it from food and kept it in medicines on supply grounds. In the book’s terms, the first brain, the gut, absorbs that exposure at full concentration; the second brain in the skull barely registers it.

    Measura does not measure excipient exposure. It is read from the product record by the prescriber and pharmacist.

    Can daily NSAIDs injure the small bowel without anyone noticing?

    NSAID enteropathy is the injury least likely to reach a problem list. In 40 healthy volunteers given two weeks of a standard NSAID dose, capsule enteroscopy found new pathology in 68% and mucosal breaks in 40%, and fecal calprotectin rose above normal in 75%. In an unselected health-check cohort, aspirin users had small-bowel mucosal breaks at 36.9% against 6.3%, an odds ratio of 6.17. Co-prescribed acid suppression did not protect the small bowel; injury was 2.7 times more frequent with celecoxib plus rabeprazole than with celecoxib plus placebo. The one agent with a healing signal, misoprostol, achieved complete healing in 28.6% against 9.5%.

    The counterevidence deserves its tier. A 2026 randomized trial found indomethacin did not raise mannitol-based permeability in healthy volunteers, yet symptom scores rose from 15.5 to 17.3 with an interval excluding zero. The cohort was healthy, dosing lasted six days, and the placebo arms were small. The practice’s position is that the camera findings govern the older multi-drug patient such trials exclude. Capsule endoscopy and calprotectin are gastrointestinal studies performed elsewhere and are not part of the Measura library.

    Can medications change the gut microbiome?

    Polypharmacy leaves reproducible microbial fingerprints. Across 1,883 human fecal metagenomes, 19 of 41 drugs associated with microbial features; after correcting for concurrent use, the signal contracted to 47 associations involving six drugs, and no drug altered richness. In 4,198 people sampled twice, polypharmacy-related community structures shifted with drug initiation and recovered with cessation. A depletion once proposed as a microbial marker of major depression was explained, in 1,802 people, by SSRI/SNRI status. Any microbiome result in a medicated patient has to be read against the bag. Measura does not run stool or microbiome testing.

    What does a baseline measurement add to deprescribing?

    The audit question with the most clinical weight is whether each indication still holds, and that is a measurement question. Measura contributes to the terrain side of it, not to drug toxicity:

    • Laboratory panels re-establish the metabolic state the metformin and statin were started for and give a dated baseline before any taper or substitution.
    • Arterial stiffness and endothelial function testing adds a direct vascular measurement alongside office blood pressure for patients on antihypertensive and lipid therapy.
    • Bioimpedance body composition matters because the enteropathy data are not only about drugs. In the same health-check cohort, obesity carried an odds ratio of 2.30 (1.38 to 3.92) for small-bowel breaks and smoking 1.85. Adiposity is a modifiable driver of metaflammation that a medication review never records.
    • Indirect calorimetry replaces an estimated resting energy expenditure with a measured one when fatigue has been attributed to age.

    Findings change management in concrete ways. A metabolic panel that has normalized reopens the indication discussion for a drug started years earlier. A body-composition result moves weight and tobacco into the same plan as the medication changes. A documented baseline makes it possible to tell, after a reformulation, whether anything moved. Reading guidance sits in interpreting the report.

    Building it into the visit

    The multi-drug older adult is commonly seen at an annual wellness visit, which many practices already use for a medication review. Attaching a standing measurement protocol to that review keeps it reproducible instead of dependent on whichever clinician has time. Standing orders can define the trigger, such as a daily-medication count, a pharmacologically managed gastrointestinal symptom, or unexplained fatigue, and annual wellness visit integration covers where results land in the encounter. Practices running cognitive assessment and fall prevention pathways can add metabolic and body-composition measurement to the same visit, and the record of what was measured and acted on supports MIPS quality reporting.

    Every study summarized here, with its limits and the results that argue the other way, is in the Deep Dive companion. The next chapter moves from the bag to the nerve that reports on it, covered for clinicians in why the LF/HF ratio is not vagal tone.

    Frequently asked questions

    What does deprescribing mean?

    Deprescribing is the planned review of a patient’s medications to decide which can be reduced, substituted, reformulated or stopped. It is usually organized around the drug list: interactions, duplications and criteria for older adults. The list alone does not show whether the reason each drug was started still holds, so a current baseline measurement belongs in the review. The ordering physician owns every deprescribing decision.

    Which patients should be measured before a deprescribing review?

    Prioritize older adults on several daily agents, especially when a gastrointestinal symptom is being managed with another drug or fatigue has been attributed to age without a workup. In one US analysis, 39.0% of adults over 65 took at least five prescriptions daily, so a written trigger works better than clinician recall. See standing orders: making screening reproducible.

    Does Measura detect NSAID enteropathy or excipient intolerance?

    No. Small-bowel injury needs capsule endoscopy or related gastrointestinal studies, and excipient questions are answered from the product record. Measura measures the metabolic, vascular, body-composition and autonomic terrain of the same patient, which informs whether each indication still holds and gives a baseline for judging any change. See clinical rationale.

    How should a negative permeability trial be weighed against capsule findings?

    As a result in a different population. The 2026 indomethacin trial enrolled healthy volunteers for six days with small placebo arms, and symptom scores still rose. Capsule studies found mucosal breaks in 40% of healthy volunteers after two weeks and visible injury in 71% of chronic users. The older multi-drug patient resembles neither trial cohort closely. See specialty applications.

    Can a microbiome result be interpreted in a patient on many drugs?

    Only against the medication list. Proton pump inhibitors, metformin, antibiotics and laxatives showed the strongest associations in human cohorts, and a microbial signal once linked to depression turned out to track antidepressant use in 1,802 people. A result read without the bag risks labeling a prescription as a disease. See physician questions.

    How should measurement be documented for quality programs?

    Record the trigger, the measurements obtained, the dated values and the management decision each one informed, including a decision to continue a drug. That record supports value-based and quality programs as documentation of what was measured and acted on, without implying that a measurement replaced clinical judgment. See HEDIS and value-based care.

    Measure the indication before revisiting it

    Learn how the Measura protocol adds metabolic, vascular and body-composition baselines to a practice’s medication review and annual wellness workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Reker, D., Blum, S. M., Steiger, C., Anger, K. E., Sommer, J. M., Fanikos, J., & Traverso, G. (2019). “Inactive” ingredients in oral medications. Science Translational Medicine, 11(483), eaau6753. https://doi.org/10.1126/scitranslmed.aau6753
    • Pottel, J., Armstrong, D., Zou, L., Fekete, A., Huang, X.-P., Torosyan, H., Bednarczyk, D., Whitebread, S., Bhhatarai, B., Liang, G., Jin, H., Ghaemi, S. N., Slocum, S., Lukacs, K. V., Irwin, J. J., Berg, E. L., Giacomini, K. M., Roth, B. L., Shoichet, B. K., & Urban, L. (2020). The activities of drug inactive ingredients on biological targets. Science, 369(6502), 403–413. https://doi.org/10.1126/science.aaz9906
    • Bettini, S., Boutet-Robinet, E., Cartier, C., Coméra, C., Gaultier, E., Dupuy, J., Naud, N., Taché, S., Grysan, P., Reguer, S., Thieriet, N., Réfrégiers, M., Thiaudière, D., Cravedi, J. P., Carrière, M., Audinot, J. N., Pierre, F. H., Guzylack-Piriou, L., & Houdeau, E. (2017). Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon. Scientific Reports, 7, 40373. https://doi.org/10.1038/srep40373
    • Maiden, L., Thjodleifsson, B., Theodors, A., Gonzalez, J., & Bjarnason, I. (2005). A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology, 128(5), 1172–1178. https://doi.org/10.1053/j.gastro.2005.03.020
    • Sun, X., Wang, F., Liu, J., Wu, L., Wang, Z., Chen, X., Wang, M., & Zeng, Q. (2022). Risk factors for small-intestinal mucosal breaks beyond aspirin. Journal of Gastroenterology and Hepatology, 37(8), 1596–1602. https://doi.org/10.1111/jgh.15892
    • Watanabe, T., Fujiwara, Y., & Chan, F. K. L. (2019). Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. Journal of Gastroenterology, 55(5), 481–495. https://doi.org/10.1007/s00535-019-01657-8
    • Camilleri, M., Busciglio, I., Carlson, P., Dilmaghani, S., Lupianez-Merly, C., Yang, D. Y., Ryks, M., Ferber, M., Houamel, D., Perot, S., & Montestruc, F. (2026). Indomethacin fails to increase intestinal permeability in healthy volunteers. Clinical and Translational Gastroenterology, 17(1), e00944. https://doi.org/10.14309/ctg.0000000000000944
    • Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., Kurilshikov, A., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications, 11(1), 362. https://doi.org/10.1038/s41467-019-14177-z
    • Nagata, N., Nishijima, S., Miyoshi-Akiyama, T., Kojima, Y., Kimura, M., Aoki, R., Ohsugi, M., Ueki, K., Miki, K., Iwata, E., Hayakawa, K., Ohmagari, N., Oka, S., Mizokami, M., Itoi, T., Kawai, T., Uemura, N., & Hattori, M. (2022). Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology, 163(4), 1038–1052. https://doi.org/10.1053/j.gastro.2022.06.070
    • Natasha, E. E., Mulder, D., Fehse, L., Winter, N. R., Fisch, L., Welzel, M., Bang, C., Meinert, S., Flinkenflügel, K., Borgers, T., Goltermann, J., Leehr, E. J., Culmsee, C., Stein, F., Thomas-Odenthal, F., Usemann, P., Teutenberg, L., Nenadic, I., Straube, B., … Bloemendaal, M. (2026). The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder. Communications Medicine, 6(1). https://doi.org/10.1038/s43856-026-01782-5

    Related reading